abstract_id,abstract_title,session_title,ground_truth,approach_1_success,approach_1_indication,approach_1_confidence,approach_1_word_count,approach_1_length,approach_1_clinical_terms,approach_1_complexity,approach_1_has_abbreviations,approach_1_has_parentheses,approach_1_error,inter_model_avg_similarity,inter_model_consensus,similarity_o3_vs_Gemini-2.5-pro,approach_1_indication_response
147495,The Burden Of Sickle Cell Disease (Scd) On Patients In Ghana And Nigeria Compared With Other Low-/Middle-Income And High-Income Countries: Results From The Sickle Cell World Assessment Survey (Sway),Sickle Cell Disease,Sickle Cell Disease,True,Sickle Cell Disease,0.98,3,19,1,0.25,False,False,,1.0,High,1.0,Sickle Cell Disease
213047,Parkinson's Disease and the Impact on Urologic Health in Older Adults,Geriatric Urological Society (GUS),Elderly Parkinson's Disease,True,Older Adult Parkinson's Disease,0.98,4,31,1,0.3,False,False,,1.0,High,1.0,Older Adult Parkinson's Disease
294973,Changing GEC Patient Care with IO plus Chemotherapy in First-Line,MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy,First-Line Gastrointestinal Cancer,True,First-Line Gastroesophageal Cancer,0.98,3,34,1,0.25,False,False,,1.0,High,1.0,First-Line Gastroesophageal Cancer
147511,Narsoplimab (Oms721) Treatment Contributes To Improvements In Organ Function In Adult Patients With High-Risk Transplant-Associated Thrombotic Microangiopathy,Stem Cell Transplantation - Clinical,,True,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy,0.98,5,64,0,0.25,False,False,,1.0,High,1.0,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy
180285,Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy,Bone Marrow Failure: Poster I,Severe Aplastic Anemia,True,Severe Aplastic Anemia,0.98,3,22,1,0.25,False,False,,1.0,High,1.0,Severe Aplastic Anemia
327727,The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed AML,1.0,3,19,1,0.25,True,False,,0.666666667,Moderate,0.666666667,Newly Diagnosed AML
393216,"Surgical Quality For Patients (Pts) Treated With Neoadjuvant Chemotherapy Vs Chemoradiation For Locally Advanced Rectal Cancer (Larc): Prospect (Ncctg N1048, Alliance)",Colorectal Cancer,Locally Advanced Rectal Cancer,True,Locally Advanced Rectal Cancer,0.99,4,30,2,0.4,False,False,,1.0,High,1.0,Locally Advanced Rectal Cancer
147461,Depth Of Response And Mrd Status In Ultra High-Risk Myeloma And Plasma Cell Leukemia Treated With Dara-Cvrd And Augmented Autologous Transplant: Results Of The Risk-Stratified Uk Optimum/Muknine Trial,Myeloma And Other Monoclonal Gammopathies - Clinical,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,True,Ultra High-Risk Myeloma;;Ultra High-Risk Plasma Cell Leukemia,0.98,7,61,2,0.55,False,False,,1.0,High,1.0,Ultra High-Risk Myeloma;;Ultra High-Risk Plasma Cell Leukemia
393219,"Effectiveness And Safety Of Rectal Arterial Infusion Chemotherapy Combined With Anti-Pd1 Antibody For Microsatellite Stable Locally Advanced Rectal Cancer: Early Outcome Report Of A Two-Stage, Single Armed, Phase II Study (Raic)",Colorectal Cancer,Microsatellite Stable Locally Advanced Rectal Cancer,True,Microsatellite Stable Locally Advanced Rectal Cancer,0.98,6,52,2,0.5,False,False,,1.0,High,1.0,Microsatellite Stable Locally Advanced Rectal Cancer
180260,Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis,"Clonal Hematopoiesis, Aging and Inflammation: Poster I",RUNX1-Familial Platelet Disorder;;Myeloid Malignancy,True,RUNX1-Familial Platelet Disorder with Myeloid Malignancies,0.98,6,58,1,0.4,False,False,,1.0,High,1.0,RUNX1-Familial Platelet Disorder with Myeloid Malignancies
147482,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,Myeloproliferative Neoplasms - Clinical,First-Line Myelofibrosis,True,First-Line Myelofibrosis;; Myelofibrosis Previously Treated with Ruxolitinib,0.98,7,76,1,0.45,False,False,,0.717557252,High,0.717557252,First-Line Myelofibrosis;; Myelofibrosis Previously Treated with Ruxolitinib
327732,Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Adult Acute Myeloid Leukemia,True,Adult UBTF Tandem Duplication-Positive AML,0.98,5,42,1,0.35,True,False,,0.288888889,Low,0.288888889,Adult UBTF Tandem Duplication-Positive AML
147508,Belumosudil For Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy: The Rockstar Study (Kd025-213),Stem Cell Transplantation - Clinical,Chronic Graft-Versus Host Disease,True,Third-Line or Later Chronic Graft-Versus Host Disease,0.98,7,53,2,0.55,False,False,,0.559322034,Moderate,0.559322034,Third-Line or Later Chronic Graft-Versus Host Disease
327741,Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",NPM1-Mutant Acute Myeloid Leukemia,True,Elderly NPM1-Mutated Acute Myeloid Leukemia,0.95,5,43,2,0.45,False,False,,1.0,High,1.0,Elderly NPM1-Mutated Acute Myeloid Leukemia
262190,"Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor Of Wild-Type And C481S Mutated Bruton Tyrosine Kinase For B-Cell Malignancies: Efficacy And Safety Of The Phase 2 Dose-Expansion Bellwave-001 Study",Chronic lymphocytic leukemia and related disorders - Clinical,B-Cell Malignancy,True,Bruton Tyrosine Kinase Wild Type/C481S-Mutated B-Cell Malignancies,0.98,7,66,0,0.35,False,False,,0.385542169,Low,0.385542169,Bruton Tyrosine Kinase Wild Type/C481S-Mutated B-Cell Malignancies
180298,"Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria",Bone Marrow Failure: Poster I,Paroxysmal Nocturnal Hemoglobinuria,True,Paroxysmal Nocturnal Hemoglobinuria,1.0,3,35,0,0.15,False,False,,1.0,High,1.0,Paroxysmal Nocturnal Hemoglobinuria
213104,What Clinical Innovations and Other Interventions Are Needed?,Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology,,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
393329,A Phase 1 Study Of Bal0891 As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Solid Tumors.,Developmental Therapeutics,Advanced Solid Tumor,True,Advanced Solid Tumor,0.98,3,20,2,0.35,False,False,,1.0,High,1.0,Advanced Solid Tumor
229467,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",Vaccines and Immunity against Bacteria and Parasites,Clostridioides Difficile Infection,True,Elderly Clostridioides Difficile Infection,0.95,4,42,0,0.2,False,False,,1.0,High,1.0,Elderly Clostridioides Difficile Infection
147554,Antibodies To Pegylated E. Coli Asparaginase Predict The Occurrence Of Hypersensitivity Reactions In High-Risk Patients Undergoing The Consolidation Phase Of The Aieop-Bfm All 2009 Protocol.,Acute Lymphoblastic Leukemia - Clinical,High-Risk Acute Lymphoblastic Leukemia,True,High-Risk Acute Lymphoblastic Leukemia,0.98,4,38,2,0.4,False,False,,0.710280374,High,0.710280374,High-Risk Acute Lymphoblastic Leukemia
327760,Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Newly Diagnosed IDH-Mutated TP53-Mutated Acute Myeloid Leukemia,True,Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia,0.98,7,58,3,0.65,True,False,,1.0,High,1.0,Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia
262209,Real-Life Outcomes Of Ponatinib Treatment In Patients With Chronic Myeloid Leukemia (Cml) Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All): 5-Year-Data From A Belgian Registry,Chronic myeloid leukemia - Clinical,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.98,7,77,4,0.75,False,False,,1.0,High,1.0,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia
327789,"Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity","Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Mixed Phenotypic Acute Leukemia,True,Mixed Phenotypic Acute Leukemia,1.0,4,31,2,0.4,False,False,,1.0,High,1.0,Mixed Phenotypic Acute Leukemia
393283,"A Phase I Study Of Safety, Pharmacokinetics, And Pharmacodynamics Of Scr-6920, A Protein Arginine Methyltransferase 5(Prmt5) Inhibitor, In Patients With Advanced Malignant Tumors",Developmental Therapeutics,Advanced Malignant Tumor,True,Advanced Malignant Tumor,0.98,3,24,2,0.35,False,False,,0.979591837,High,0.979591837,Advanced Malignant Tumor
180300,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,Bone Marrow Failure: Poster I,Adult Late-Onset Telomere Biology Disorder,True,Adult Late Onset Telomere Biology Disorders,0.98,6,43,1,0.4,False,False,,1.0,High,1.0,Adult Late Onset Telomere Biology Disorders
262206,Bosutinib Dose Optimization In The Second-Line Treatment Of Elderly Cml Patients: Extended 3-Year Follow-Up And Final Results Of The Best Study,Chronic myeloid leukemia - Clinical,Second-Line Elderly Chronic Myeloid Leukemia,True,Second-Line Elderly Chronic Myeloid Leukemia,0.98,5,44,2,0.45,False,False,,0.818181818,High,0.818181818,Second-Line Elderly Chronic Myeloid Leukemia
147521,Thrombophilia As Risk Factor For Asparaginase Related Venous Thromboembolism In Pediatric And Young Adult Patients Affected By Acute Lymphoblastic Leukemia,Thrombosis And Vascular Biology - Biology & Translational Research,Pediatric Young Adult Venous Thromboembolism,True,Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia,0.98,8,80,2,0.6,False,False,,1.0,High,1.0,Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia
327778,The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia After Induction Chemotherapy,0.95,6,51,3,0.6,False,False,,0.602739726,Moderate,0.602739726,Acute Myeloid Leukemia After Induction Chemotherapy
393291,"Preclinical Evaluation Of Hlx42, A Novel Egfr-Targeting Adc, For Cetuximab Or Tki Resistant Cancer",Developmental Therapeutics,Cancer,True,Cetuximab-Resistant EGFR-Positive Cancer;;TKI-Resistant EGFR-Positive Cancer,0.9,5,76,3,0.55,True,False,,0.770491803,High,0.770491803,Cetuximab-Resistant EGFR-Positive Cancer;;TKI-Resistant EGFR-Positive Cancer
311376,Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease",Rheumatoid Arthritis,True,Anti-CCP Positive Pre-Rheumatoid Arthritis,0.95,4,42,1,0.3,True,False,,0.909090909,High,0.909090909,Anti-CCP Positive Pre-Rheumatoid Arthritis
295042,Invited Discussant 1312O and 1313O,Proffered Paper session: Policy and preventive strategies,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
229509,Osteoclast differentiation alters monocyte inflammatory responses to Staphylococcus aureus,Cells of the Innate Immune System,Staphylococcus Aureus Infection,True,Staphylococcus aureus Infection,0.95,3,31,0,0.15,False,False,,1.0,High,1.0,Staphylococcus aureus Infection
180358,Targeting Metabolic Vulnerabilities in Primary Effusion Lymphoma Using the Novel Nucleoside Analog 6-Eti,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I,Primary Effusion Lymphoma,True,Primary Effusion Lymphoma,0.99,3,25,1,0.25,False,False,,1.0,High,1.0,Primary Effusion Lymphoma
311447,CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus,Abstracts: SLE - Treatment,Refractory Systemic Lupus Erythematosus,True,Refractory Systemic Lupus Erythematosus,1.0,4,39,1,0.3,False,False,,1.0,High,1.0,Refractory Systemic Lupus Erythematosus
327817,Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric Acute Myeloid Leukemia,True,Pediatric Acute Myeloid Leukemia,1.0,4,32,2,0.4,False,False,,1.0,High,1.0,Pediatric Acute Myeloid Leukemia
376946,Automated Metrics From The Electronic Health Record Enable Evaluation Of Palliative Care In Patients With Acute Myeloid Leukaemia: A Data Science Approach,Quality of life and palliative care,Acute Myeloid Leukemia,True,Acute Myeloid Leukaemia,1.0,3,23,1,0.25,False,False,,1.0,High,1.0,Acute Myeloid Leukaemia
262259,Multiplex Deletion Of Myeloid Antigens Cd33 And Cll-1 By Crispr/Cas9 In Human Hematopoietic Stem Cells Highlights The Potential Of Next-Generation Transplants For Aml Treatment.,"Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,1.0,High,1.0,Acute Myeloid Leukemia
409754,Audience Q&A,Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases,,True,Complement-Mediated Kidney Diseases,0.98,3,35,1,0.25,False,False,,1.0,High,1.0,Complement-Mediated Kidney Diseases
229493,Pan-coronavirus neutralizing S2 human monoclonal antibodies and utility of direct respiratory administration as combination therapy with S1 antibodies against SARS-CoV-2,Vaccination and immunotherapy against COVID-19,SARS-CoV-2 Infection,True,COVID-19,0.95,1,8,0,0.05,True,False,,1.0,High,1.0,COVID-19
327823,Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",NPM1-Mutated Acute Myeloid Leukemia,True,NPM1-Mutated MRD-Positive Acute Myeloid Leukemia,0.98,5,48,3,0.55,True,False,,0.843373494,High,0.843373494,NPM1-Mutated MRD-Positive Acute Myeloid Leukemia
311449,Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares,Abstracts: SLE - Treatment,Systemic Lupus Erythematosus,True,Flaring Systemic Lupus Erythematosus,0.95,4,36,0,0.2,False,False,,0.8,High,0.8,Flaring Systemic Lupus Erythematosus
311433,Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population,"Abstracts: SLE - Diagnosis, Manifestations, and Outcomes II: Complications",Systemic Lupus Erythematosus,True,Severe COVID-19;; Systemic Lupus Erythematosus,0.98,5,46,1,0.35,True,False,,0.567567568,Moderate,0.567567568,Severe COVID-19;; Systemic Lupus Erythematosus
376961,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,Acute myeloid leukemia - Clinical,Elderly Newly Diagnosed High-Risk Secondary Acute Myeloid Leukaemia,True,Older Adult Newly Diagnosed High-Risk Acute Myeloid Leukaemia;;Older Adult Newly Diagnosed Secondary Acute Myeloid Leukaemia,0.98,15,124,2,0.95,False,False,,0.991803279,High,0.991803279,Older Adult Newly Diagnosed High-Risk Acute Myeloid Leukaemia;;Older Adult Newly Diagnosed Secondary Acute Myeloid Leukaemia
393371,Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc),Gynaecological Cancers,Advanced High-Grade Ovarian Cancer,True,Advanced High Grade CCNE1-Amplified BRCA Wild-Type/HRD-Negative Ovarian Cancer,0.98,8,78,4,0.8,True,False,,0.53125,Moderate,0.53125,Advanced High Grade CCNE1-Amplified BRCA Wild-Type/HRD-Negative Ovarian Cancer
393337,Efficacy And Safety Of High-Dose Chemotherapy As Second Or Subsequent Salvage Therapy In Relapsed Or Refractory Germ Cell Cancer Patients: A Multicentric Analysis,Germ Cell (Testicular) Cancer And Penile Cancer,Relapsed or Refractory Germ Cell Cancer,True,Second-Line or Later Relapsed/Refractory Germ Cell Cancer,0.95,7,57,3,0.65,False,False,,0.654545455,Moderate,0.654545455,Second-Line or Later Relapsed/Refractory Germ Cell Cancer
213157,Society for the Study of Male Reproduction (SSMR),Society for the Study of Male Reproduction (SSMR),,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
393407,Mental And Socioeconomic Burden In Co-Parents And Children Of Patients With Endometrial And Cervical Cancer: A Swedish Population-Based Study,Gynaecological Cancers,Childhood Endometrial Cancer;;Childhood Cervical Cancer,True,Endometrial Cancer;;Cervical Cancer,0.98,3,35,1,0.25,False,False,,1.0,High,1.0,Endometrial Cancer;;Cervical Cancer
262328,"Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) Btk Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 Bruin Study",Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,Previously Treated Mantle Cell Lymphoma,True,Previously Treated Mantle Cell Lymphoma,0.99,5,39,2,0.45,False,False,,1.0,High,1.0,Previously Treated Mantle Cell Lymphoma
344232,Chair Introduction,Intercepting Molecular Residual Disease in the Clinic,,True,,0.1,0,0,0,0.0,False,False,,0.0,Low,0.0,
327865,Clinical Significance of IGH Clonality Analysis with RNA Sequencing in B-Cell Precursor Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",B-Cell Precursor Acute Lymphoblastic Leukemia,True,B-Cell Precursor Acute Lymphoblastic Leukemia,0.98,5,45,2,0.45,False,False,,1.0,High,1.0,B-Cell Precursor Acute Lymphoblastic Leukemia
327859,Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Acute Lymphoblastic Leukemia,True,High Hyperdiploid Acute Lymphoblastic Leukemia,0.98,5,46,2,0.45,False,False,,1.0,High,1.0,High Hyperdiploid Acute Lymphoblastic Leukemia
180390,Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Venous Thromboembolism;;Acute Myeloid Leukemia,True,Non-APL Acute Myeloid Leukemia,0.98,4,30,2,0.4,True,False,,0.697674419,Moderate,0.697674419,Non-APL Acute Myeloid Leukemia
180389,Safety and Efficacy of Isavuconazole in Patients Aged 65 Years or Older with Invasive Fungal Disease: A Post-Hoc Analysis from the VITAL and Secure Studies,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Elderly Invasive Fungal Disease,True,Elderly Invasive Fungal Disease,0.98,4,31,1,0.3,False,False,,1.0,High,1.0,Elderly Invasive Fungal Disease
393382,The Predictive Role Of Circulating Exosomal Pd-L1 In Cervical Cancer Immunotherapy,Gynaecological Cancers,Cervical Cancer,True,Cervical Cancer,0.95,2,15,1,0.2,False,False,,0.491803279,Moderate,0.491803279,Cervical Cancer
393400,Tumor-Informed Ctdna Detection As A Predictive Marker For Postoperative Residual Disease In Epithelial Ovarian Cancer: A Feasibility Study,Gynaecological Cancers,Epithelial Ovarian Cancer,True,Residual Epithelial Ovarian Cancer,0.98,4,34,1,0.3,False,False,,1.0,High,1.0,Residual Epithelial Ovarian Cancer
262320,"Brentuximab Vedotin, Etoposide, Solumedrol, High Dose Ara-C & Platinum Followed By Hdt & Apbsct For Refractory/Relapsed Hodgkin Lymphoma Patients: Long-Term Results Of The Geltamo Group Breshap Study",Hodgkin lymphoma - Clinical,Refractory/Relapsed Hodgkin Lymphoma,True,Refractory/Relapsed Hodgkin Lymphoma,0.98,3,36,3,0.45,False,False,,0.808988764,High,0.808988764,Refractory/Relapsed Hodgkin Lymphoma
327866,The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Relapsed KMT2A-Rearranged Infant Childhood Leukemia,True,Infant Relapsed KMT2A-Rearranged Acute Lymphoblastic Leukemia;;Childhood Relapsed KMT2A-Rearranged Acute Lymphoblastic Leukemia,0.98,11,127,3,0.85,False,False,,0.701030928,High,0.701030928,Infant Relapsed KMT2A-Rearranged Acute Lymphoblastic Leukemia;;Childhood Relapsed KMT2A-Rearranged Acute Lymphoblastic Leukemia
180403,Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia,True,Newly Diagnosed Adult Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,0.98,9,80,4,0.85,False,False,,0.925,High,0.925,Newly Diagnosed Adult Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
262300,Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity,"Hematopoiesis, stem cells and microenvironment",,True,Helios-Mutated Germline Pleiotropic Defects Of Immunity,0.98,6,55,0,0.3,False,False,,0.511627907,Moderate,0.511627907,Helios-Mutated Germline Pleiotropic Defects Of Immunity
393379,Correlation Between Chemotherapy Response Score (Crs) And Germline Brca1/2 (Gbrca) Status In Women Diagnosed With Figo Stage Iiic/Iv High-Grade Serous Ovarian Cancer (Hgsoc),Gynaecological Cancers,Stage IIIc/IV High-Grade Serous Ovarian Cancer,True,FIGO Stage IIIc/IV High Grade Serous Ovarian Cancer,0.98,8,51,3,0.7,True,False,,1.0,High,1.0,FIGO Stage IIIc/IV High Grade Serous Ovarian Cancer
409825,Advocacy and Policy: What Can Nephrologists and National Organizations Do?,Winning Team: The Nephrology Workforce for the 21st Century,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
311500,"A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis",Abstracts: Vasculitis - ANCA-Associated,ANCA-Associated Vasculitis,True,ANCA-Associated Vasculitis,1.0,2,26,0,0.1,True,False,,1.0,High,1.0,ANCA-Associated Vasculitis
311504,Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR <=20 in the Avacopan ADVOCATE Trial,Abstracts: Vasculitis - ANCA-Associated,ANCA-Associated Vasculitis,True,ANCA-Associated Vasculitis with Baseline eGFR <=20,0.98,6,50,0,0.3,True,False,,0.979591837,High,0.979591837,ANCA-Associated Vasculitis with Baseline eGFR <=20
180429,Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients Based on Peripheral Blast Clearance Rate: A Phase II Single-Arm Study,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Elderly Acute Myeloid Leukemia,True,Elderly Acute Myeloid Leukemia,0.98,4,30,2,0.4,False,False,,1.0,High,1.0,Elderly Acute Myeloid Leukemia
229586,Microbiota drive concomitant expression of IL-17 and the inhibitory receptor PD-1 to regulate effector functions of gd17 cells in the intestine,Neonatal and Fetal Mucosal Immunity,,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
327904,BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas,Lymphomas: Translational-Molecular and Genetic: Poster II,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma,True,BCL6-Rearranged Indolent B-Cell Lymphoma,0.98,4,40,1,0.3,False,False,,1.0,High,1.0,BCL6-Rearranged Indolent B-Cell Lymphoma
327877,The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric T-Cell Acute Lymphoblastic Leukemia,True,Pediatric T-Cell Acute Lymphoblastic Leukemia,0.98,5,45,2,0.45,False,False,,1.0,High,1.0,Pediatric T-Cell Acute Lymphoblastic Leukemia
147677,Validation And Clinical Application Of An Unsupervised Analysis Approach To Measurable Residual Disease Testing In Acute Myeloid Leukemia,Acute Myeloid Leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.98,3,22,2,0.35,False,False,,1.0,High,1.0,Acute Myeloid Leukemia
180437,Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Acute Myeloid Leukemia,True,Adult Newly Diagnosed AML,0.98,4,25,1,0.3,True,False,,1.0,High,1.0,Adult Newly Diagnosed AML
295132,"Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen, and what duration?","The three ""Ws"" of early breast cancer management",Luminal Breast Cancer,True,Luminal Breast Cancer,0.98,3,21,1,0.25,False,False,,1.0,High,1.0,Luminal Breast Cancer
147689,Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd,Acute Myeloid Leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia with Persistent MRD,0.98,6,42,2,0.5,True,False,,1.0,High,1.0,Acute Myeloid Leukemia with Persistent MRD
147649,Phase 1 First-In-Human Study Of Irreversible Flt3 Inhibitor Ff-10101-01 In Relapsed Or Refractory Acute Myeloid Leukemia,Acute Myeloid Leukemia - Clinical,Relapsed/Refractory Acute Myeloid Leukemia,True,Relapsed Or Refractory Acute Myeloid Leukemia,0.98,6,45,4,0.7,False,False,,0.965517241,High,0.965517241,Relapsed Or Refractory Acute Myeloid Leukemia
377049,"Therapeutic Potential And Strategies Of Pim447, A Pan-Pim Inhibitor, Targeting Refractory Myeloid Leukemia With Kit-Driven T(8/21)",Acute myeloid leukemia - Biology & Translational Research,Refractory Myeloid Leukemia,True,Refractory Kit-Driven T(8/21) Myeloid Leukemia,0.98,5,46,2,0.45,False,True,,0.661764706,Moderate,0.661764706,Refractory Kit-Driven T(8/21) Myeloid Leukemia
180445,Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",IDH1-Mutated IDH2-Mutated Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed IDH1/IDH2-Mutated Acute Myeloid Leukemia,0.98,6,56,3,0.6,False,False,,0.704402516,High,0.704402516,Newly Diagnosed IDH1/IDH2-Mutated Acute Myeloid Leukemia
180442,"Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study","Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed Adult Acute Myeloid Leukemia Unfit for Intensive Therapy,0.98,10,72,4,0.9,False,False,,0.916666667,High,0.916666667,Newly Diagnosed Adult Acute Myeloid Leukemia Unfit for Intensive Therapy
344332,Chair Introduction,"Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials",,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
213255,Microbiome and BPH,Society of Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
164102,MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study,LBA02: Late-breaking Abstract II - Malignant,Intermediate-Risk Prostate Cancer,True,Intermediate-Risk Prostate Cancer,1.0,3,33,1,0.25,False,False,,1.0,High,1.0,Intermediate-Risk Prostate Cancer
409842,Do All Collagen Variants Cause Glomerular Disease?,Collagen IV Conundrums: Genetic Variants and Clinical Management,,True,Glomerular Disease,0.95,2,18,1,0.2,False,False,,1.0,High,1.0,Glomerular Disease
180465,Integrated Transcriptomics and Proteomics Identifies Therapeutic Targets in Pediatric Acute Myeloid Leukemia,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric Acute Myeloid Leukemia,True,Pediatric Acute Myeloid Leukemia,0.98,4,32,2,0.4,False,False,,1.0,High,1.0,Pediatric Acute Myeloid Leukemia
213252,Rapid Fire,Society of Benign Prostate Disease,Benign Prostate Disease,True,Benign Prostate Disease,0.95,3,23,1,0.25,False,False,,1.0,High,1.0,Benign Prostate Disease
327929,Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas,Lymphomas: Translational-Molecular and Genetic: Poster III,B-Cell Lymphoma,True,B-Cell Lymphoma,0.95,2,15,1,0.2,False,False,,1.0,High,1.0,B-Cell Lymphoma
213248,"BPH Guidelines: Conflict and Contrast in the AUA, EAU, NICE BPH Guidelines",Society of Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.98,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
295167,Circulating tumour DNA for monitoring of response to neoadjuvant chemotherapy in patients with high grade serous ovarian carcinoma,Thermo Fisher Scientific - Connecting patients everywhere to precision oncology,High Grade Serous Ovarian Carcinoma,True,High Grade Serous Ovarian Carcinoma,0.98,5,35,2,0.45,False,False,,1.0,High,1.0,High Grade Serous Ovarian Carcinoma
377096,"Azacitidine, Venetoclax And Gilteritinib For Patients With Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia: A Subgroup Analysis From A Phase Ii Study",Acute myeloid leukemia - Clinical,Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia,True,Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia,1.0,6,51,3,0.6,False,False,,1.0,High,1.0,Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia
311555,Itchy Rash and Starry Eyed,Adult Thieves Market Poster,,True,Adult Itchy Rash,0.9,3,16,0,0.15,False,False,,1.0,High,1.0,Adult Itchy Rash
180473,Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,1.0,High,1.0,Acute Myeloid Leukemia
164086,Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,LBA01: Late-breaking Abstract I - Benign,,True,Chronic Residual Fragments,0.85,3,26,1,0.25,False,False,,0.0,Low,0.0,Chronic Residual Fragments
377088,Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,Infections in hematology (incl. supportive care/therapy),Haematological Disease,True,Haematological Disease With Prolonged Viral Shedding,0.98,6,52,1,0.4,False,False,,1.0,High,1.0,Haematological Disease With Prolonged Viral Shedding
180478,Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,True,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia,0.98,5,52,2,0.45,False,False,,1.0,High,1.0,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
180529,Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated with Third-Line Therapy in the United States: A Real-World EHR Study,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Third-Line Follicular Lymphoma,True,Third-Line Follicular Lymphoma,1.0,3,30,1,0.25,False,False,,1.0,High,1.0,Third-Line Follicular Lymphoma
311577,Q&A,Adult Thieves Market: Show Me Your Best Cases,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
213274,"The ""Butterfly"" transurethral retraction device for BPH - over 1 year follow up",MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
213291,Minimally Invasive and Endoscopic Therapies for Benign Prostatic Hyperplasia: Head-to-Head Comparison of Short-Term Outcomes by Network Meta-Analysis,MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
262425,Familial Erythrocytoses In The Czech Republic - Genetic Characterization And Hepcidin Regulation,"Iron metabolism, deficiency and overload",Familial Erythrocytosis,True,Familial Erythrocytosis,0.98,2,23,0,0.1,False,False,,1.0,High,1.0,Familial Erythrocytosis
377144,A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study,Clinical updates in ALL,Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia,True,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.98,7,67,4,0.75,False,False,,1.0,High,1.0,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia
393489,Efficacy Of Notch Inhibitors (Ni) Relative To Prior Systemic Therapy Or Observation In Patients (Pts) With Recurrent/Metastatic (R/M) Adenoid Cystic Carcinoma (Acc),"Head and neck cancers, excl. thyroid",Recurrent/Metastatic Adenoid Cystic Carcinoma,True,Recurrent/Metastatic Adenoid Cystic Carcinoma,0.98,4,45,1,0.3,False,False,,1.0,High,1.0,Recurrent/Metastatic Adenoid Cystic Carcinoma
377121,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,Stem cell transplantation - Clinical,,True,Pediatric Endothelial Damage After Allogeneic Hematopoietic Stem Cell Transplantation,0.95,9,85,0,0.45,False,False,,0.495575221,Moderate,0.495575221,Pediatric Endothelial Damage After Allogeneic Hematopoietic Stem Cell Transplantation
180497,A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy,Lymphomas: Translational-Molecular and Genetic: Poster I,Follicular Lymphoma,True,Follicular Lymphoma,0.98,2,19,1,0.2,False,False,,1.0,High,1.0,Follicular Lymphoma
377120,Axicabtagene Ciloleucel Versus Tisagenlecleucel Car-T Cells In Relapsed Or Refractory Diffuse Large B Cell Lymphoma,"Gene therapy, cellular immunotherapy and vaccination - Clinical",Relapsed/Refractory Diffuse Large B Cell Lymphoma,True,Relapsed or Refractory Diffuse Large B Cell Lymphoma,1.0,8,52,3,0.7,False,False,,1.0,High,1.0,Relapsed or Refractory Diffuse Large B Cell Lymphoma
327983,Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study,Lymphomas: Translational-Non-Genetic: Poster II,Relapsed/Refractory Non-Hodgkin Lymphoma,True,Relapsed/Refractory Non-Hodgkin Lymphoma,0.98,3,40,3,0.45,False,False,,1.0,High,1.0,Relapsed/Refractory Non-Hodgkin Lymphoma
311607,"UTI Biofilms, Amyloid, and Lupus Flares",Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes,,True,Urinary Tract Infection with Biofilms;;Amyloidosis;;Lupus Flare,0.95,6,63,0,0.3,False,False,,0.712121212,High,0.712121212,Urinary Tract Infection with Biofilms;;Amyloidosis;;Lupus Flare
180501,Differential Gene Expression in Circulating T-Cells in Long-Term Adolescent/Young Adult Hodgkin Lymphoma (AYAHL) Survivors and Their Unaffected Twins,Lymphomas: Translational-Non-Genetic: Poster I,Adolescent/Young Adult Hodgkin Lymphoma,True,Adolescent and Young Adult Hodgkin Lymphoma,0.98,6,43,1,0.4,False,False,,0.895833333,High,0.895833333,Adolescent and Young Adult Hodgkin Lymphoma
229667,The biological mechanisms of metformin effects on aging-associated inflammation in obesity,Immuneregulation-Innate Immune Responses,,True,Aging-Associated Inflammation,0.9,2,29,0,0.1,False,False,,1.0,High,1.0,Aging-Associated Inflammation
327998,"Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma",Lymphomas: Translational-Non-Genetic: Poster III,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma,True,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma,0.98,7,61,3,0.65,False,False,,0.576923077,Moderate,0.576923077,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma
147785,"Haemophilia B Leyden, An Age-Related Mechanism For An Increase Of Factor Ix: Case Report And Literature Review",Bleeding Disorders (Congenital And Acquired),Haemophilia B Leyden,True,Haemophilia B Leyden,0.99,3,20,0,0.15,False,False,,1.0,High,1.0,Haemophilia B Leyden
409919,Audience Q&A,What's Complement Got to Do with It? ANCA Vasculitis and the Complement System,ANCA Vasculitis,True,ANCA Vasculitis,0.95,2,15,0,0.1,True,False,,1.0,High,1.0,ANCA Vasculitis
328016,A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders,Lymphomas: Translational-Non-Genetic: Poster I,Lymphoproliferative Disorder,True,Lymphoproliferative Disorder,0.95,2,28,1,0.2,False,False,,1.0,High,1.0,Lymphoproliferative Disorder
311657,Challenges in Psoriatic Disease: When Skin and Joint Symptoms Are Divergent,Challenges in Psoriatic Disease: Divergent Skin and Joints,Psoriatic Disease,True,Psoriatic Disease With Divergent Skin and Joint Symptoms,0.95,8,56,1,0.5,False,False,,0.465753425,Moderate,0.465753425,Psoriatic Disease With Divergent Skin and Joint Symptoms
213348,Thulium YAG vs Thulium Fiber Laser Enucleation of the Prostate (ThuLEP vs TFLEP): a Multi-institution Trial to Compare Intra and Early Postoperative Outcomes.,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
328014,Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader,Lymphomas: Translational-Non-Genetic: Poster I,Lymphoma,True,Cutaneous T-Cell Lymphoma,0.98,3,25,1,0.25,False,False,,1.0,High,1.0,Cutaneous T-Cell Lymphoma
213341,Trends in holmium laser enucleation of the prostate for treatment of benign prostatic hyperplasia,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
295266,How to incorporate digital medicine in survivorship care after breast cancer,How to incorporate digital medicine in survivorship care after breast cancer,Breast Cancer,True,Breast Cancer,0.98,2,13,1,0.2,False,False,,0.634146341,Moderate,0.634146341,Breast Cancer
147776,"Discovery Of Hbw-3-20, The First Reversible Inhibitor Of Bruton'S Tyrosine Kinase (Btk) With High Brain Exposure",Aggressive Non-Hodgkin Lymphoma - Clinical,Aggressive Non-Hodgkin Lymphoma,True,Aggressive Non-Hodgkin Lymphoma,0.98,3,31,1,0.25,False,False,,1.0,High,1.0,Aggressive Non-Hodgkin Lymphoma
213344,En-Bloc enucleation technique with early apical release and urinary sphincter preservation using Pulse modulation (Virtual Basket) vs En-Bloc HoLEP,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,1.0,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
262464,Potentiating Anti-Cd20 Monoclonal Antibody Therapy By Targeting Complement C3 Activation Fragments Covalently Deposited On Lymphoma Cells,Lymphoma Biology & Translational Research,Lymphoma ,True,Lymphoma,0.95,1,8,1,0.15,False,False,,1.0,High,1.0,Lymphoma
377189,Changings In Genetic Definition And Management Of Acquired Aplastic Anemia: A Single Center Experience,Bone marrow failure syndromes incl. PNH - Clinical,Acquired Aplastic Anemia,True,Acquired Aplastic Anemia,0.98,3,24,0,0.15,False,False,,1.0,High,1.0,Acquired Aplastic Anemia
147782,Investigation Of Preterm Intraventricular Hemorrhage-Induced Inflammatory Response And Microrna Levels In Human Choroid Plexus Epithelial Cells,Bleeding Disorders (Congenital And Acquired),Congenital Bleeding Disorder;;Acquired Bleeding Disorder,True,Intraventricular Hemorrhage,0.95,2,27,0,0.1,False,False,,1.0,High,1.0,Intraventricular Hemorrhage
328003,Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion,Lymphomas: Translational-Non-Genetic: Poster III,High Grade B Cell Lymphoma,True,High Grade B Cell Lymphoma,0.98,5,26,2,0.45,False,False,,1.0,High,1.0,High Grade B Cell Lymphoma
213317,How does the type of urinary diversion affect health related quality of life (HRQOL) in the course of four years after radical cystectomy? - A propensity score-matched analysis,MP03: Bladder Cancer: Invasive I,Invasive Bladder Cancer,True,Invasive Bladder Cancer,0.95,3,23,1,0.25,False,False,,0.647887324,Moderate,0.647887324,Invasive Bladder Cancer
262514,Clinical Significance Of Routine High-Resolution Strucural Variant Profiling In Myelodysplastic Syndromes,Myelodysplastic syndromes - Clinical,Myelodysplastic Syndrome,True,Myelodysplastic Syndrome,0.98,2,24,1,0.2,False,False,,0.979591837,High,0.979591837,Myelodysplastic Syndrome
295316,Gender differences in colorectal cancer screening,Sex and gender differences in oncology: From prevention to care,Colorectal Cancer,True,Colorectal Cancer,1.0,2,17,1,0.2,False,False,,1.0,High,1.0,Colorectal Cancer
409981,Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories,Power of Large Biorepositories in Diabetic Kidney Disease,Diabetic Kidney Disease,True,Diabetic Kidney Disease,0.95,3,23,1,0.25,False,False,,1.0,High,1.0,Diabetic Kidney Disease
147837,Influence Of Inflammatory Cytokines On S100A Proteins Expression In Cll Patients,Chronic Lymphocytic Leukemia And Related Disorders - Biology & Translational Research,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,1.0,3,28,2,0.35,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia
164220,Panel Discussion,Society for Pediatric Urology (SPU),,True,Pediatric Urology,0.9,2,17,0,0.1,False,False,,1.0,High,1.0,Pediatric Urology
344465,Chairperson,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
147864,Effectiveness And Safety Of Ibrutinib In Chronic Lymphocytic Leukemia (Cll) And Mantle Cell Lymphoma (Mcl) In Belgian Routine Clinical Practice With A 3-Year Follow-Up,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,True,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,0.98,5,50,3,0.55,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma
344467,Reprogramming the tumor-immune microenvironment by targeting galectin-glycan interactions,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,,True,Tumor,0.85,1,5,1,0.15,False,False,,0.294117647,Low,0.294117647,Tumor
377194,Arginine Deprivation Induces Acquisition Of A Senescent Phenotype And Favors Genomic Instability In Multiple Myeloma Plasma Cells,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
262527,Characterization Of Multiple Myeloma Cell Lines With Acquired-Resistance To Proteasome Inhibitors Highlights A Link Between Resistance And Metabolic Deregulation,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
409986,Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1,A Rocky Course: Bones and Stones Through the Life Span,Cystinuria;;Primary Hyperoxaluria Type 1;;Genetic Stone Disease,True,Cystinuria;;PH1,0.98,1,15,0,0.05,False,False,,0.528301887,Moderate,0.528301887,Cystinuria;;PH1
311696,Proposed ACR/EULAR Classification Criteria for CNO,Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO),Pediatric Chronic Nonbacterial Osteomyelitis,True,Pediatric Chronic Nonbacterial Osteomyelitis (CNO);;Pediatric Chronic Recurrent Multifocal Osteomyelitis (CRMO),0.98,10,111,1,0.6,True,True,,0.485714286,Moderate,0.485714286,Pediatric Chronic Nonbacterial Osteomyelitis (CNO);;Pediatric Chronic Recurrent Multifocal Osteomyelitis (CRMO)
409966,Controversies in the Management of Dyslipidemia in Children with CKD,Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?,Childhood Dyslipidemia,True,Dyslipidemia in Pediatric Chronic Kidney Disease,0.98,6,48,2,0.5,False,False,,0.775510204,High,0.775510204,Dyslipidemia in Pediatric Chronic Kidney Disease
262522,Runx1 Variants With High Variant Allele Frequency In Myeloid Neoplasms. Germline Or Not?,Myelodysplastic syndromes - Clinical,Myeloid Neoplasm,True,Runx1-Mutated Germline Myeloid Neoplasms with High Variant Allele Frequency,0.95,9,75,0,0.45,False,False,,0.369565217,Low,0.369565217,Runx1-Mutated Germline Myeloid Neoplasms with High Variant Allele Frequency
393583,"Comparative Efficacy Of Systemic Sequential Regorafenib After Sorafenib Or Lenvatinib Treatment Failure For Advanced Hepatocellular Carcinoma: A Retrospective, Multi-Center, Real-World Study",Hepatocellular Carcinoma (Hcc),Advanced Hepatocellular Carcinoma,True,Sorafenib- or Lenvatinib-Refractory Advanced Hepatocellular Carcinoma,0.95,6,69,3,0.6,False,False,,0.653465347,Moderate,0.653465347,Sorafenib- or Lenvatinib-Refractory Advanced Hepatocellular Carcinoma
164266,Welcome and Introductory Remarks,Society for Basic Urologic Research (SBUR),,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
393652,Adjuvant Treatment With Anti-Pd-1 In Acral Melanoma Patients: A Nationwide Study,Melanoma And Other Skin Tumours,Acral Melanoma,True,Acral Melanoma,0.99,2,14,0,0.1,False,False,,1.0,High,1.0,Acral Melanoma
393627,Tertiary Lymphoid Structures Localization And Maturation Heterogeneities Correlate With Divergent Clinical Outcomes And Immune Responses Of Clear Cell Renal Cell Carcinoma,Investigational Immunotherapy,Clear Cell Renal Cell Carcinoma,True,Clear Cell Renal Cell Carcinoma,1.0,5,31,1,0.35,False,False,,1.0,High,1.0,Clear Cell Renal Cell Carcinoma
262569,High Responses Rates With Single Agent Belantamab Mafodotin In Relapsed Systemic Al Amyloidosis,Myeloma and other monoclonal gammopathies - Clinical,Relapsed Systemic Al Amyloidosis,True,Relapsed Systemic Al Amyloidosis,0.99,4,32,1,0.3,False,False,,1.0,High,1.0,Relapsed Systemic Al Amyloidosis
393639,Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database,Investigational Immunotherapy,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
164257,Controversies in the Management of High-Risk Prostate Cancer,Society of Urologic Oncology (SUO),High-Risk Prostate Cancer,True,High-Risk Prostate Cancer,1.0,3,25,1,0.25,False,False,,1.0,High,1.0,High-Risk Prostate Cancer
262579,Survival Outcomes Of Patients With Multiple Myeloma In France: A Cohort Study Using The French National Healthcare Database (Snds),Myeloma and other monoclonal gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
213405,Medications mostly associated with haematuria: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries,"MP07: Bladder & Urethra: Anatomy, Physiology & Pharmacology",Haematuria,True,Haematuria,1.0,1,10,0,0.05,False,False,,1.0,High,1.0,Haematuria
377263,Role Of Interleukin 6 And Angiopoietins 1 And 2 In The Evolution Of Patients Diagnosed With Multiple Myeloma,Myeloma and other monoclonal gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
295345,Presentation by Expert,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,Chronic Lymphocytic Leukemia,True,First-Line Chronic Lymphocytic Leukemia,0.98,4,39,2,0.4,False,False,,1.0,High,1.0,First-Line Chronic Lymphocytic Leukemia
262567,Efficacy And Safety Of Daratumumab Monotherapy In Newly Diagnosed Patients With Stage 3B Light Chain Amyloidosis: A Phase 2 Study By The European Myeloma Network,Myeloma and other monoclonal gammopathies - Clinical,Newly Diagnosed Stage 3B Light Chain Amyloidosis,True,Newly Diagnosed Stage 3B Light Chain Amyloidosis,0.99,7,48,2,0.55,False,False,,1.0,High,1.0,Newly Diagnosed Stage 3B Light Chain Amyloidosis
328106,Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Relapsed/Refractory Mantle Cell Lymphoma,True,Relapsed/Refractory Mantle Cell Lymphoma,0.98,4,40,3,0.5,False,False,,0.661157025,Moderate,0.661157025,Relapsed/Refractory Mantle Cell Lymphoma
213425,Long Term Fertility Implications Following Adolescent Testicular Torsion: A Retrospective Analysis of a New York State All-Payer Database,MP08: Pediatric Urology: Penis & Scrotum,,True,Adolescent Testicular Torsion,0.98,3,29,0,0.15,False,False,,1.0,High,1.0,Adolescent Testicular Torsion
393651,Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy After Relapse On A Prior Adjuvant Checkpoint Inhibitor And Subsequent Surgical Resection In Patients With Braf V600-Mutated Stage Iii/Iv Melanoma,Melanoma And Other Skin Tumours,Braf V600-Mutated Stage III/IV Melanoma,True,Relapsed Stage III/IV BRAF V600-Mutated Melanoma,0.98,6,48,2,0.5,True,False,,0.729166667,High,0.729166667,Relapsed Stage III/IV BRAF V600-Mutated Melanoma
262577,Incidence And Clinical Outcome Of Sars-Cov-2 Infection After Vaccination In Patients With Monoclonal Gammopathy Of Undetermined Significance (Mgus),Myeloma and other monoclonal gammopathies - Clinical,Sars-Cov-2 Infection;;Monoclonal Gammopathy,True,Vaccinated Monoclonal Gammopathy Of Undetermined Significance,0.9,6,61,0,0.3,False,False,,0.789473684,High,0.789473684,Vaccinated Monoclonal Gammopathy Of Undetermined Significance
311747,Q&A,"Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management",,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
295352,How to write and respond to a critical peer review,Young Oncologist Brunch 2: How to write and respond to a critical peer review,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
344518,BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules,Late-Breaking Research: Chemistry,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
328150,Late Effects Comparison between Two Chemotherapy Regimens for Hodgkin Lymphoma,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,Hodgkin Lymphoma,True,Hodgkin Lymphoma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Hodgkin Lymphoma
328146,"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)",Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,Early Stage Classic Hodgkin Lymphoma,True,Early Stage Classic Hodgkin Lymphoma,1.0,5,36,3,0.55,False,False,,1.0,High,1.0,Early Stage Classic Hodgkin Lymphoma
410057,Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm,Maternal and Environmental Factors: Effect on Kidney Formation and Function,Kidney Injury,True,Kidney Injury,0.98,2,13,0,0.1,False,False,,1.0,High,1.0,Kidney Injury
295362,State of the art first-line management of patients with advanced RCC,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,Advanced Renal Cell Carcinoma,True,First-Line Advanced Renal Cell Carcinoma,0.98,5,40,2,0.45,False,False,,1.0,High,1.0,First-Line Advanced Renal Cell Carcinoma
295365,Q&A and discussion,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,Advanced Renal Cancer,True,Advanced Renal Cancer,0.98,3,21,2,0.35,False,False,,0.72,High,0.72,Advanced Renal Cancer
377273,Preliminary Exploration On Lag-3 Expression Of Bone Marrow-Derived Macrophages In Severe Aplastic Anemia,Bone marrow failure syndromes incl. PNH - Biology & Translational Research,Severe Aplastic Anemia,True,Severe Aplastic Anemia,0.98,3,22,1,0.25,False,False,,1.0,High,1.0,Severe Aplastic Anemia
213447,Quality of Information in Spanish on BRCA and Genetic Testing in Prostate Cancer on YouTube,MP09: Prostate Cancer: Detection & Screening I,Prostate Cancer,True,BRCA-Mutated Prostate Cancer,0.95,3,28,1,0.25,True,False,,0.697674419,Moderate,0.697674419,BRCA-Mutated Prostate Cancer
295375,TNBC today: How can we increase survival for a very heterogenous and aggressive disease?,"Gilead and Kite Oncology - Redefining the Lines of TNBC, Real-world management: improving survival for patients with metastatic TNBC",Triple-Negative Breast Cancer,True,Metastatic Aggressive Triple-Negative Breast Cancer,0.95,5,51,2,0.45,False,False,,0.879120879,High,0.879120879,Metastatic Aggressive Triple-Negative Breast Cancer
344512,Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss,"New Insights into Cancer Initiation, Evolution, Therapy and Survivorship through Big Data Analysis",Cancer ,True,Sporadic Cancer with p53 Loss,0.9,5,29,1,0.35,False,False,,0.342857143,Low,0.342857143,Sporadic Cancer with p53 Loss
410042,Common Variants in Mendelian Disease Genes as Risk Factors for CKD,"APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases",Chronic Kidney Disease,True,Chronic Kidney Disease Associated with Mendelian Gene Variants,0.9,8,62,2,0.6,False,False,,0.523809524,Moderate,0.523809524,Chronic Kidney Disease Associated with Mendelian Gene Variants
377287,"A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study",Infections and SCT complications,Febrile Neutropenia,True,Blood Stream Infection in Hematologic Patients with Febrile Neutropenia,0.98,9,71,1,0.55,False,False,,0.992907801,High,0.992907801,Blood Stream Infection in Hematologic Patients with Febrile Neutropenia
393665,First-Line Nivolumab Plus Ipilimumab In Advanced Melanoma Patients Previously Treated With Adjuvant Systemic Therapy.,Melanoma And Other Skin Tumours,Advanced Melanoma,True,First-Line Previously Treated Advanced Melanoma,0.85,5,47,2,0.45,False,False,,0.839285714,High,0.839285714,First-Line Previously Treated Advanced Melanoma
410094,Value of Urine Microscopy in Clinical Practice: Illustration by Cases,"Liquid ""Gold,"" Urinary Sediment Microscopy: Current Utility of an Old Tool",,True,,0.5,0,0,0,0.0,False,False,,0.0,Low,0.0,
147934,"Selection, Expansion, And New Pretreatment Of Human Natural Killer Cells With Anti-Cd38 Monoclonal Antibody For Efficient Treatment Of Multiple Myeloma.","Gene Therapy, Cellular Immunotherapy And Vaccination - Biology & Translational Research",Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
328177,Primary Cutaneous Gamma-Delta T-Cell Lymphoma (PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,True,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,1.0,5,45,1,0.35,False,False,,1.0,High,1.0,Primary Cutaneous Gamma-Delta T-Cell Lymphoma
295399,"Triple, double and monotherapy: what is the sequence for best outcomes?",Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,True,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,0.95,6,48,2,0.5,False,False,,1.0,High,1.0,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer
393710,Transforming Growth Factor-Beta-1 And Soluble Co-Inhibitory Immune Checkpoints As Putative Drivers Of Immune Suppression In Advanced Basal Cell Carcinoma,Melanoma And Other Skin Tumours,Advanced Basal Cell Carcinoma,True,Advanced Basal Cell Carcinoma,0.98,4,29,2,0.4,False,False,,1.0,High,1.0,Advanced Basal Cell Carcinoma
213478,A Technique to Prevent Stomal Stenosis in Reconstructive Urology,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",,True,Pediatric Stomal Stenosis,0.95,3,25,0,0.15,False,False,,0.75,High,0.75,Pediatric Stomal Stenosis
213480,Survival analysis among Utah residents with spina bifida born between 1950 and 2015,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Spina Bifida,True,Pediatric Spina Bifida,0.95,3,22,0,0.15,False,False,,0.705882353,High,0.705882353,Pediatric Spina Bifida
262634,T Cell Response And Omicron Variant Neutralisation Following Vaccination Against Sars-Cov-2 In Patients With Chronic Myeloid Disorders,Myeloproliferative neoplasms - Biology & Translational Research,Chronic Myeloid Disorder,True,Chronic Myeloid Disorder,0.98,3,24,2,0.35,False,False,,0.979591837,High,0.979591837,Chronic Myeloid Disorder
295405,Therapeutic approaches in unresectable / advanced HCC,AstraZeneca - Immunotherapy: the evolving treatment landscape in hepatobiliary cancers,Unresectable/Advanced Hepatocellular Carcinoma,True,Unresectable Hepatocellular Carcinoma,0.98,3,37,1,0.25,False,False,,1.0,High,1.0,Unresectable Hepatocellular Carcinoma
262640,Peripheral Blood Cytotoxic T Cells Show Early Exhausted Features In Myelofibrosis Patients,Myeloproliferative neoplasms - Biology & Translational Research,Myelofibrosis ,True,Myelofibrosis,0.95,1,13,0,0.05,False,False,,1.0,High,1.0,Myelofibrosis
311791,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) III,Fellows-In-Training: Roundtables,,True,,0.99,0,0,0,0.0,False,False,,0.0,Low,0.0,
213477,Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate (Dx/Ha) In The Pediatric Patient: Results Of A Single Center Analysis With Long Term Follow Up,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Pediatric Neurogenic Bladder,True,Pediatric Neurogenic Bladder,0.95,3,28,0,0.15,False,False,,0.658823529,Moderate,0.658823529,Pediatric Neurogenic Bladder
311793,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV,Fellows-In-Training: Roundtables,Adult Pediatric Rheumatic Disease,True,,0.1,0,0,0,0.0,False,False,,0.0,Low,0.0,
213484,Short and Long Term Renal Outcomes in Clinically Matched Cohorts of Newborns with PUV Managed by Primary Vesicostomy Versus Primary Valve Ablation,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Neonatal Posterior Urethral Valve,True,Neonatal Posterior Urethral Valves,0.98,4,34,0,0.2,False,False,,0.895522388,High,0.895522388,Neonatal Posterior Urethral Valves
180704,Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx),Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I,Relapsed/Refractory Chronic Lymphocytic Leukemia,True,Relapsed/Refractory Chronic Lymphocytic Leukemia,0.98,4,48,4,0.6,False,False,,0.662068966,Moderate,0.662068966,Relapsed/Refractory Chronic Lymphocytic Leukemia
311808,Roundtable 08 - How to Establish a Career Niche IV,Fellows-In-Training: Roundtables,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
262689,Responses To Avapritinib In Patients With Advanced Systemic Mastocytosis: Histopathologic Analyses From Explorer And Pathfinder Clinical Studies,Myeloproliferative neoplasms - Clinical,Advanced Systemic Mastocytosis,True,Advanced Systemic Mastocytosis,1.0,3,30,1,0.25,False,False,,1.0,High,1.0,Advanced Systemic Mastocytosis
295427,Metastatic non-small-cell lung cancer: Discussion / Q&A,ESMO Clinical Practice Guidelines session 2,Metastatic Non-Small-Cell Lung Cancer,True,Metastatic Non-Small-Cell Lung Cancer,1.0,4,37,1,0.3,False,False,,1.0,High,1.0,Metastatic Non-Small-Cell Lung Cancer
148009,Real-World Treatment Patterns And Outcomes Of 3455 Previously Untreated Mantle Cell Lymphoma Patients In Us Routine Clinical Practice,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Previously Untreated Mantle Cell Lymphoma,True,Previously Untreated Mantle Cell Lymphoma,0.98,5,41,2,0.45,False,False,,1.0,High,1.0,Previously Untreated Mantle Cell Lymphoma
311815,Roundtable 10 - Early Career Niche in Pediatric Rheumatology: Amplified Pain Syndrome III,Fellows-In-Training: Roundtables,Pediatric Amplified Pain Syndrome III,True,Pediatric Amplified Pain Syndrome III,0.98,5,37,1,0.35,True,False,,0.942857143,High,0.942857143,Pediatric Amplified Pain Syndrome III
180787,Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
295442,Invited Discussant LBA54 and 972O,"Proffered Paper session: NSCLC, metastatic",Metastatic Non-Small Cell Lung Cancer,True,Metastatic NSCLC,0.98,2,16,0,0.1,True,False,,0.566037736,Moderate,0.566037736,Metastatic NSCLC
262704,Low Serum Bdnf Levels Are Associated With Lower Platelets' Cd62P Reactivity And Increased Bleeding Tendency In Patients With Gaucher Disease,Platelet disorders,Gaucher Disease,True,Gaucher Disease With Increased Bleeding Tendency,0.9,6,48,1,0.4,False,False,,0.476190476,Moderate,0.476190476,Gaucher Disease With Increased Bleeding Tendency
393731,Evaluation Of The Transcriptomic Presence Of Tumor Associated Antigens (Taas) From Antibody Drug Conjugates (Adcs) And Pd-L1 In Melanoma: Options For New Clinical Opportunities,Melanoma And Other Skin Tumours,Melanoma,True,Melanoma,0.95,1,8,0,0.05,False,False,,1.0,High,1.0,Melanoma
262670,Higher Estimated Plasma Volume Status Is Associated With Increased Thrombotic Risk And Impaired Survival In Patients With Primary Myelofibrosis,Myeloproliferative neoplasms - Clinical,Primary Myelofibrosis,True,Primary Myelofibrosis,0.9,2,21,0,0.1,False,False,,1.0,High,1.0,Primary Myelofibrosis
148013,Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Hairy Cell Leukemia,True,Previously Treated Hairy Cell Leukemia,0.98,5,38,2,0.45,False,False,,0.763157895,High,0.763157895,Previously Treated Hairy Cell Leukemia
328231,"The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial",Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,True,Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,0.98,6,50,3,0.6,False,False,,0.648275862,Moderate,0.648275862,Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
393754,"A Phase II Single-Arm Interventional Trial Evaluating The Activity And Safety Of Cabozantinib (Cbz) Plus Temozolomide (Tmz) In Lung And Gastroenteropancreatic Neuroendocrine Neoplasms (Gep-Nens) Progressed After Ssa Therapy, Everolimus, Sunitinib Or Prrt: Cabotem Trial",Neuroendocrine Tumours,Lung Neuroendocrine Neoplasm;;Gastroenteropancreatic Neuroendocrine Neoplasm ,True,Progressive Lung Neuroendocrine Neoplasms;; Progressive Gastroenteropancreatic Neuroendocrine Neoplasms,0.98,8,103,0,0.4,False,False,,0.841666667,High,0.841666667,Progressive Lung Neuroendocrine Neoplasms;; Progressive Gastroenteropancreatic Neuroendocrine Neoplasms
377385,Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy,Chronic myeloid leukemia - Clinical,Severe Thrombocytopenia;;Chronic Phase Chronic Myeloid Leukemia,True,Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia,0.95,6,54,3,0.6,False,False,,0.706896552,High,0.706896552,Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
377370,Subclonal And Clonal Variants In Tp53 And Kras Combined With Poor Treatment Response Identify A Subgroup Of Ultra-High-Risk Patients Of Pediatric T-Lymphoblastic Leukemia (T-All),Acute lymphoblastic leukemia - Biology & Translational Research,TP53-Mutated KRAS-Mutated Ultra High-Risk Pediatric T-Lymphoblastic Leukemia,True,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia with TP53 and KRAS Variants,0.95,10,78,1,0.6,True,False,,0.78125,High,0.78125,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia with TP53 and KRAS Variants
311878,Roundtable 24 - Salivary Lip Biopsies in Practice IV,Fellows-In-Training: Roundtables,,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
262728,Factors Associated With A Lymphoma Diagnosis Prior To Biopsy,"Quality of life, palliative care, ethics and health economics",Lymphoma,True,Lymphoma,0.98,1,8,1,0.15,False,False,,1.0,High,1.0,Lymphoma
410176,Earlier Intervention in Diabetic Kidney Disease Management Using the In Vitro Diagnostic Test PromarkerD Shows Economic Health Benefits over Current Standard of Care,Improving Clinical Outcomes in Diabetic Kidney Disease,Diabetic Kidney Disease,True,Diabetic Kidney Disease,1.0,3,23,1,0.25,False,False,,1.0,High,1.0,Diabetic Kidney Disease
377420,Expression Of The Long Non-Coding Rna Malat1 In Chronic Lymphocytic Leukemia,Chronic lymphocytic leukemia and related disorders - Biology & Translational Research,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,1.0,3,28,2,0.35,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia
295477,5-hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions,Mini Oral session: Basic science & translational research,,True,Cancer,0.9,1,6,1,0.15,False,False,,1.0,High,1.0,Cancer
229946,Low birth weight is associated with sperm DNA fragmentation and assisted reproductive technology outcomes in primary infertile men - results of a cross-sectional study,PD09: Infertility: Epidemiology & Evaluation I,,True,Primary Male Infertility,0.98,3,24,0,0.15,False,False,,1.0,High,1.0,Primary Male Infertility
180799,"Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma",Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.98,4,32,2,0.4,False,False,,1.0,High,1.0,Newly Diagnosed Multiple Myeloma
262717,Metabolic Abnormality And Glucocorticoid Receptor Modulation Of Myeloid-Derived Suppressor Cells In Immune Thrombocytopenia Patients And An Active Murine Model,Platelet disorders,Immune Thrombocytopenia,True,Immune Thrombocytopenia,0.95,2,23,0,0.1,False,False,,1.0,High,1.0,Immune Thrombocytopenia
180817,"Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone",Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,1.0,4,32,2,0.4,False,False,,1.0,High,1.0,Newly Diagnosed Multiple Myeloma
262725,Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States,"Quality of life, palliative care, ethics and health economics",Beta-Thalassemia,True,Transfusion-Dependent-Beta-Thalassemia,1.0,1,38,0,0.05,False,False,,1.0,High,1.0,Transfusion-Dependent-Beta-Thalassemia
344653,Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma,Diagnostic and Prognostic Biomarkers 1,Malignant Uterine Leiomyosarcoma,True,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma,0.98,4,50,0,0.2,False,False,,1.0,High,1.0,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma
393814,Personalized Tumor-Informed Circulating Tumor Dna (Ctdna) Analysis For Molecular Residual Disease (Mrd) Detection In Resected Non-Small Cell Lung Cancer (Nsclc) With Common Driver Genes,"Nsclc, Early Stage",Resected Non-Small Cell Lung Cancer,True,Early Stage Resected Non-Small Cell Lung Cancer with Common Driver Genes,0.98,11,72,3,0.85,False,False,,0.654205607,Moderate,0.654205607,Early Stage Resected Non-Small Cell Lung Cancer with Common Driver Genes
328253,"Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma",Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.98,5,49,3,0.55,False,False,,0.524064171,Moderate,0.524064171,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
328274,Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium,Aggressive Lymphomas: Clinical and Epidemiological: Poster II,Adolescent Adult Burkitt Lymphoma;;Adolescent Adult Leukemia,True,Adolescent Burkitt Lymphoma;;Adolescent Leukemia;;Adult Burkitt Lymphoma;;Adult Leukemia,0.98,7,88,2,0.55,False,False,,0.712121212,High,0.712121212,Adolescent Burkitt Lymphoma;;Adolescent Leukemia;;Adult Burkitt Lymphoma;;Adult Leukemia
328247,Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.98,5,49,3,0.55,False,False,,0.924528302,High,0.924528302,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
377438,Pharmacodynamic Activity Of Gen3014 (Hexabody-Cd38) In Patients With Multiple Myeloma Supports Enhanced Complement Dependent Cytotoxicity Of Gen3014 Compared To Daratumumab,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
295539,Patient and Public Involvement in Cancer Research: The Needs and Perceptions of Older Adults Living with and After Cancer,Supportive care and symptom management,Older Adult Cancer,True,Older Adult Cancer,0.95,3,18,1,0.25,False,False,,1.0,High,1.0,Older Adult Cancer
164457,"Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings",Society for Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostate Disease,0.98,3,23,1,0.25,False,False,,1.0,High,1.0,Benign Prostate Disease
164460,The Advent of Directed Medical BPH Care-How Alpha Blockers were Developed,Society for Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.98,3,28,0,0.15,False,False,,1.0,High,1.0,Benign Prostatic Hyperplasia
180842,The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation,Experimental Transplantation: Basic and Translational: Poster I,Graft-Versus-Host Disease,True,Gut Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation,0.98,8,79,1,0.5,False,False,,0.928104575,High,0.928104575,Gut Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation
393830,Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study,"Nsclc, Early Stage",Stage I-III Resectable Non-Small Cell Lung Cancer,True,Resectable Stage 1-3 Non-Small Cell Lung Cancer,0.98,7,47,2,0.55,False,False,,1.0,High,1.0,Resectable Stage 1-3 Non-Small Cell Lung Cancer
344667,Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma,Diagnostic and Prognostic Biomarkers 1,Metastatic Melanoma,True,Metastatic Melanoma,0.95,2,19,0,0.1,False,False,,1.0,High,1.0,Metastatic Melanoma
311906,Q&A,Genetic Predisposition and the Balance Between Infection and Autoimmunity,,True,Genetic Predisposition to Infection and Autoimmunity,0.85,6,52,0,0.3,False,False,,0.666666667,Moderate,0.666666667,Genetic Predisposition to Infection and Autoimmunity
213605,Is Excretory Phase Computerized Tomography Important for Evaluation of High Grade Renal Trauma?: Results from the Traumatic Renal Injury Collaboration for Kids (TRICK),MP17: Pediatric Urology: Upper & Lower Urinary Tract,Traumatic Renal Injury,True,Childhood High Grade Renal Trauma,0.98,5,33,1,0.35,False,False,,1.0,High,1.0,Childhood High Grade Renal Trauma
393827,Predicting Pd-L1 Expression Using [18F]Fdg Pet/Ct In Early Stage Non-Small Cell Lung Cancer (Nsclc).,"Nsclc, Early Stage",Early Stage Non-Small Cell Lung Cancer,True,Early Stage Non-Small Cell Lung Cancer,0.98,6,38,3,0.6,False,False,,0.633333333,Moderate,0.633333333,Early Stage Non-Small Cell Lung Cancer
393832,Neoadjuvant Therapy With Anti-Pd-1/Pd-L1 Plus Platinum-Base Chemotherapy For Resectable Stage Ii-Iii Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis Of Randomized Clinical Trials,"Nsclc, Early Stage",Resectable Stage II-III Non-Small Cell Lung Cancer,True,Resectable Stage II-III Non-Small Cell Lung Cancer,0.98,7,50,2,0.55,True,False,,0.927835052,High,0.927835052,Resectable Stage II-III Non-Small Cell Lung Cancer
213592,Are pre-operative urine cultures and cystoscopies before ureteral reimplantation clinically useful or cost effective?,MP17: Pediatric Urology: Upper & Lower Urinary Tract,,True,Pediatric Upper and Lower Urinary Tract Disease,0.6,7,47,1,0.45,False,False,,0.0,Low,0.0,Pediatric Upper and Lower Urinary Tract Disease
393826,Concordance Of Pd-L1 Expression Between Biopsy And Matched Surgical Specimen In Early-Stage Non-Small Cell Lung Cancer: Lc-Scrum-Advantage/Mrd,"Nsclc, Early Stage",Early-Stage Non-Small Cell Lung Cancer,True,Early Stage Non-Small Cell Lung Cancer,0.98,6,38,3,0.6,False,False,,0.817204301,High,0.817204301,Early Stage Non-Small Cell Lung Cancer
262759,Health-Related Quality Of Life In Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated With Iberdomide Plus Dexamethasone In A Phase 1B/2A Open-Label Dose Escalation Study,"Quality of life, palliative care, ethics and health economics",Relapsed/Refractory Multiple Myeloma ,True,Relapsed/Refractory Multiple Myeloma,0.98,3,36,3,0.45,False,False,,1.0,High,1.0,Relapsed/Refractory Multiple Myeloma
180828,Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Relapsed and/or Refractory Multiple Myeloma,True,Third-Line or Later Relapsed/Refractory Multiple Myeloma,0.98,6,56,3,0.6,False,False,,0.660550459,Moderate,0.660550459,Third-Line or Later Relapsed/Refractory Multiple Myeloma
311960,"Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity",Ignite Session 1C,,True,Systemic Autoimmunity,1.0,2,21,0,0.1,False,False,,0.791666667,High,0.791666667,Systemic Autoimmunity
213661,A Pilot Study of Outcomes after Robot-Assisted Sigmoid Vaginoplasty for Gender Dysphoria,MP20: Trauma/Reconstruction/Diversion: External Genitalia Reconstruction and Urotrauma (including transgender surgery) I,Gender Dysphoria,True,Gender Dysphoria,1.0,2,16,0,0.1,False,False,,1.0,High,1.0,Gender Dysphoria
311932,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,Psoriatic Arthritis,True,Psoriatic Arthritis,1.0,2,19,0,0.1,False,False,,1.0,High,1.0,Psoriatic Arthritis
377489,Prophylactic And Preemptive Use Of Dli Compare Favourably To Their Therapeutic Use In Adult Acute Lymphoblastic Leukemia (All) - Results Of A Multicentre Retrospective Study,Acute lymphoblastic leukemia - Clinical,Adult Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,1.0,4,34,2,0.4,False,False,,1.0,High,1.0,Adult Acute Lymphoblastic Leukemia
148116,Mesenchymal Stromal Cells As A Potential Therapeutic Tool In Enhancing Residual Healthy Haematopoiesis In Low-Risk Mds Patients,Myelodysplastic Syndromes - Biology & Translational Research,Low-Risk Myelodysplastic Syndrome,True,Low-Risk Myelodysplastic Syndromes,0.99,3,34,1,0.25,False,False,,1.0,High,1.0,Low-Risk Myelodysplastic Syndromes
164469,Photoselective Vaporization of the Prostate,Society for Benign Prostate Disease,Benign Prostate Disease,True,Benign Prostate Disease,0.98,3,23,1,0.25,False,False,,1.0,High,1.0,Benign Prostate Disease
230042,Predictive value of circulating tumor cells FTH1 gene on the efficacy of neoadjuvant chemotherapy in non-metastatic breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Non-Metastatic Breast Cancer,True,Non-Metastatic Breast Cancer,0.98,3,28,1,0.25,False,False,,1.0,High,1.0,Non-Metastatic Breast Cancer
344700,OvaPrint - a novel cfDNA methylation liquid biopsy for cancer risk assessment in high grade serous ovarian carcinoma,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,High Grade Serous Ovarian Carcinoma,True,High Grade Serous Ovarian Carcinoma,1.0,5,35,2,0.45,False,False,,1.0,High,1.0,High Grade Serous Ovarian Carcinoma
262802,Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020,Stem cell transplantation - Clinical,,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
344703,Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED),Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,Cancer,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
262793,Long-Term Follow-Up Of Dutch Patients With Sickle Cell Disease Diagnosed By Neonatal Screening - Effect On The Morbidity And Mortality In The Netherlands.,Sickle cell disease,Sickle Cell Disease,True,Neonatal Sickle Cell Disease,0.98,4,28,1,0.3,False,False,,0.808510638,High,0.808510638,Neonatal Sickle Cell Disease
230018,Breast cancer: Online education's effect on clinician ability to assess risk of recurrence and understanding the latest data.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Recurrence-Risk Breast Cancer,0.9,3,29,1,0.25,False,False,,1.0,High,1.0,Recurrence-Risk Breast Cancer
148103,Cohesin Mutations Are Associated With A Poor Prognosis Phenotype And A Worse Clinical Outcome In Low-Risk Myelodysplastic Syndromes Patients,Myelodysplastic Syndromes - Biology & Translational Research,Low-Risk Myelodysplastic Syndrome,True,Cohesin-Mutated Low-Risk Myelodysplastic Syndromes,0.98,4,50,1,0.3,False,False,,0.80952381,High,0.80952381,Cohesin-Mutated Low-Risk Myelodysplastic Syndromes
393855,First-Line Osimertinib In Patients With Egfr Mutated Lung Cancer With Uncommon Mutations (Ocelot Study - Interim Analysis),"Nsclc, Metastatic",EGFR-Mutated Lung Cancer,True,First-Line Metastatic EGFR-Mutated Non-Small Cell Lung Cancer with Uncommon Mutations,0.98,10,85,1,0.6,True,False,,0.657142857,Moderate,0.657142857,First-Line Metastatic EGFR-Mutated Non-Small Cell Lung Cancer with Uncommon Mutations
328332,Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group,Aggressive Lymphomas: Clinical and Epidemiological: Poster I,Sars-Cov-2 Infection;;Primary CNS Lymphoma,True,Primary CNS Lymphoma,0.98,3,20,1,0.25,True,False,,0.606060606,Moderate,0.606060606,Primary CNS Lymphoma
230073,Impacts of subtypes on clinical feature and outcome of male breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Local/Regional Male Breast Cancer,0.98,4,33,1,0.3,False,False,,0.705882353,High,0.705882353,Local/Regional Male Breast Cancer
410286,Differential cfDNA Methylation in Kidney Allograft Rejection,"Kidney Transplantation: Biomarkers, New and Old",,True,Kidney Allograft Rejection,0.98,3,26,0,0.15,False,False,,1.0,High,1.0,Kidney Allograft Rejection
148158,Tumor Associated Macrophages Inhibit Cd8+T Cells Immune Responses Via Pd-1/Pd-L1 Pathway In Multiple Myeloma,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
262851,Efficacy And Safety Comparison Of Calcineurin Inhibitors Used For Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation In Children With Thalassemia,Stem cell transplantation - Clinical,Thalassemia,True,Childhood Gvhd;;Childhood Thalassemia,0.98,3,37,0,0.15,False,False,,0.774193548,High,0.774193548,Childhood Gvhd;;Childhood Thalassemia
410288,Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection,"Kidney Transplantation: Biomarkers, New and Old",,True,Kidney Transplant T Cell-Mediated Rejection,0.98,5,43,0,0.25,False,False,,1.0,High,1.0,Kidney Transplant T Cell-Mediated Rejection
180933,Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",,True,Occult Abnormality,0.75,2,18,0,0.1,False,False,,0.0,Low,0.0,Occult Abnormality
230053,Neutrophil-lymphocyte ratio and prediction of pathological complete response to neoadjuvant treatment in breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Locoregional Breast Cancer,0.95,3,26,1,0.25,False,False,,0.666666667,Moderate,0.666666667,Locoregional Breast Cancer
410269,Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD,Interventions to Reduce CKD Progression,Primary Kidney Disease;;Chronic Kidney Disease,True,Chronic Kidney Disease,0.98,3,22,2,0.35,False,False,,1.0,High,1.0,Chronic Kidney Disease
213700,How is health-related quality of life affected by salvage cystectomy and urinary diversion as a last-line option for benign disease,"MP22: Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I",,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
393915,Efficacy Of First-Line Treatment Options In Advanced Her2-Altered Non-Small Cell Lung Cancer: A Multi-Center Retrospective Study,"Nsclc, Metastatic",First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer,True,First-Line Advanced Metastatic Her2-Altered Non-Small Cell Lung Cancer,0.95,8,70,2,0.6,False,False,,0.914728682,High,0.914728682,First-Line Advanced Metastatic Her2-Altered Non-Small Cell Lung Cancer
230055,Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Breast Cancer with Nodal Downstaging from cN+ to ycN0,0.98,9,53,1,0.55,False,False,,0.46728972,Moderate,0.46728972,Breast Cancer with Nodal Downstaging from cN+ to ycN0
410290,Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study,"Kidney Transplantation: Biomarkers, New and Old",Hypertension ,True,Graft Failure in Kidney Transplant Recipients with Hypertension,0.9,8,63,0,0.4,False,False,,0.61682243,Moderate,0.61682243,Graft Failure in Kidney Transplant Recipients with Hypertension
393888,Updated Patient-Reported Outcomes From The Crown Study: Analyses In First-Line Alk+ Patients With (W) And Without (W/O) Baseline Brain Metastases (Bms) And W Or W/O Central Nervous System Adverse Events (Cns Aes),"Nsclc, Metastatic",First-Line ALK-Postive Metastatic Non-Small Cell Lung Cancer,True,First-Line Metastatic ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases;; First-Line Metastatic ALK-Positive Non-Small Cell Lung Cancer without Brain Metastases,0.98,20,172,2,1.0,True,False,,0.528138528,Moderate,0.528138528,First-Line Metastatic ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases;; First-Line Metastatic ALK-Positive Non-Small Cell Lung Cancer without Brain Metastases
180932,The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",Early Cytomegalovirus Infection,True,Adult High-Risk Cytomegalovirus Infection,0.95,4,41,0,0.2,False,False,,0.598540146,Moderate,0.598540146,Adult High-Risk Cytomegalovirus Infection
148133,Venetoclax Combined With Azacitidine In The Treatment Of Relapsed/Refractory High-Risk Myelodysplastic Syndromes And Acute Myeloid Leukemia: A Retrospective Single-Center Study,Myelodysplastic Syndromes - Clinical,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory High-Risk Acute Myeloid Leukemia,True,Relapsed/Refractory High-Risk Myelodysplastic Syndromes;;Relapsed/Refractory Acute Myeloid Leukemia,0.98,7,99,5,0.85,False,False,,0.648829431,Moderate,0.648829431,Relapsed/Refractory High-Risk Myelodysplastic Syndromes;;Relapsed/Refractory Acute Myeloid Leukemia
295653,Discussion,"Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management",,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
410337,A Novel Glomerular Endothelium-Targeting Adeno-Associated Virus (AAV) Delivers Bacterial Proteinase to Treat Glomerulonephritis,"Bioengineering, Augmented Intelligence, Digital Health, and Data Science",Glomerulonephritis,True,Glomerulonephritis,1.0,1,18,0,0.05,False,False,,1.0,High,1.0,Glomerulonephritis
213726,Circulating tumor DNA is a strong predictor in patients treated with systemic therapy for urothelial carcinoma,MP23: Bladder Cancer: Invasive III,Urothelial Carcinoma,True,Stage III Invasive Urothelial Carcinoma,0.95,5,39,2,0.45,True,False,,0.677966102,Moderate,0.677966102,Stage III Invasive Urothelial Carcinoma
328439,Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,BCR-ABL-Fusion Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,1.0,3,24,2,0.35,False,False,,1.0,High,1.0,Chronic Myeloid Leukemia
328431,Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Chronic Myeloid Leukaemia,True,Chronic Myeloid Leukaemia,0.95,3,25,1,0.25,False,False,,0.979591837,High,0.979591837,Chronic Myeloid Leukaemia
393942,Recurrence Of Infusion-Related Reaction (Irrs) Associated To Avimantamab,"Nsclc, Metastatic",Metastatic Non-Small Cell Lung Cancer,True,Metastatic Nsclc,0.95,2,16,0,0.1,False,False,,0.566037736,Moderate,0.566037736,Metastatic Nsclc
410348,Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider,COVID-19: A New Understanding and Lessons Learned,COVID-19 Infection,True,COVID-19 in Dialysis Patients,0.95,4,29,1,0.3,True,False,,1.0,High,1.0,COVID-19 in Dialysis Patients
328438,Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia after Treatment Discontinuation,0.95,6,56,3,0.6,False,False,,0.6,Moderate,0.6,Chronic Myeloid Leukemia after Treatment Discontinuation
328455,Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I,Intermediate-Risk High-Risk Chronic Myeloid Leukemia,True,First-Line High-Risk Chronic Myeloid Leukemia;;First-Line Intermediate-Risk Chronic Myeloid Leukemia,0.98,9,100,2,0.65,False,False,,1.0,High,1.0,First-Line High-Risk Chronic Myeloid Leukemia;;First-Line Intermediate-Risk Chronic Myeloid Leukemia
230112,Survival trends of patients with Paget disease of the breast: A National Cancer Database (NCDB) study.,Breast Cancer-Local/Regional/Adjuvant,Paget Disease of the Breast,True,Locoregional Paget Disease of the Breast,0.9,6,40,1,0.4,False,False,,0.805970149,High,0.805970149,Locoregional Paget Disease of the Breast
148233,"Survival Among Older Patients With Previously Treated Multiple Myeloma Treated With Selinexor, Bortezomib, And Dexamethasone (Xvd) In The Boston Study",Myeloma And Other Monoclonal Gammopathies - Clinical,Elderly Previously Treated Multiple Myeloma,True,Previously Treated Elderly Multiple Myeloma,0.98,5,43,2,0.45,False,False,,1.0,High,1.0,Previously Treated Elderly Multiple Myeloma
180989,Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population,Autologous Transplantation: Clinical and Epidemiological: Poster I,,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
393929,Real-World Routine Kras Testing Practices In France For Patients (Pts) With Advanced Or Metastatic (Am) Non-Small Cell Lung Cancer (Nsclc): Data From The Esme Cohort,"Nsclc, Metastatic",Advanced Or Metastatic Non-Small Cell Lung Cancer,True,Locally Advanced Metastatic Non-Small Cell Lung Cancer,0.95,7,54,2,0.55,False,False,,1.0,High,1.0,Locally Advanced Metastatic Non-Small Cell Lung Cancer
328423,"ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase",Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II,Newly Diagnosed Ph-Positive Chronic Myelogenous Leukemia in Chronic Phase,True,Newly Diagnosed Ph Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia,0.98,8,81,4,0.8,False,False,,1.0,High,1.0,Newly Diagnosed Ph Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia
262924,A Phase 1/2 Study To Evaluate Ponatinib With Chemotherapy In Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Or With T315I Mutation,Acute lymphoblastic leukemia - Clinical,Relapsed/Intolerant Ph-Positive T315I Mutated Acute Lymphoblastic Leukemia,True,Pediatric Relapsed/Resistant Ph Chromosome-Positive or T315I-Mutated Acute Lymphoblastic Leukemia,0.98,9,97,5,0.95,False,False,,0.705454545,High,0.705454545,Pediatric Relapsed/Resistant Ph Chromosome-Positive or T315I-Mutated Acute Lymphoblastic Leukemia
344870,"A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models",Targeting the Tumor Microenvironment,Tumor ,True,Solid Tumor,0.85,2,11,1,0.2,False,False,,0.625,Moderate,0.625,Solid Tumor
410383,Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database,Kidney Transplantation: New Translational Insights,,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
377619,Discontinuation Of Treatment With Thrombopoietin Receptor Agonists In Patients With Immune Thrombocytopenia: A Single-Center Clinical Experience,Bleeding disorders (congenital and acquired),Immune Thrombocytopenia,True,Immune Thrombocytopenia,0.98,2,23,0,0.1,False,False,,1.0,High,1.0,Immune Thrombocytopenia
148272,Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients Stratified By Transplant Status Diagnosed Between 2007-2018: Real-World Analysis From The Canadian Myeloma Research Group Database,Myeloma And Other Monoclonal Gammopathies - Clinical,Newly-Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.99,4,32,2,0.4,False,False,,1.0,High,1.0,Newly Diagnosed Multiple Myeloma
213784,Rural Hospital Location is Associated with Higher Reported Prices for Ureteroscopy with Laser Lithotripsy Among Commercially Insured Patients,MP26: Stone Disease: Epidemiology & Evaluation I,Stone Disease,True,Stone Disease,0.9,2,13,1,0.2,False,False,,0.553191489,Moderate,0.553191489,Stone Disease
344862,"Mini-tumors: Pre-clinical HCI assays to screen anti-cancer drugs in the context of organoids, cancer-associated fibroblasts and immune cells",Targeting the Tumor Microenvironment,Cancer,True,Malignant Tumor,0.85,2,15,1,0.2,False,False,,0.5,Moderate,0.5,Malignant Tumor
230183,Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.,Breast Cancer-Metastatic,Hyperglycemia ,True,Metastatic Breast Cancer,0.98,3,24,1,0.25,False,False,,0.108108108,Low,0.108108108,Metastatic Breast Cancer
148257,Overall And Complete Response Rates As Potential Surrogates For Overall Survival In Relapsed Refractory Multiple Myeloma,Myeloma And Other Monoclonal Gammopathies - Clinical,Relapsed Refractory Multiple Myeloma,True,Relapsed Refractory Multiple Myeloma,0.99,4,36,3,0.5,False,False,,0.660550459,Moderate,0.660550459,Relapsed Refractory Multiple Myeloma
394023,Gut Microbiome Is Associated With The Clinical Response To Anti-Pd-1 Based Immunotherapy In Untreated Advanced Non-Small-Cell Lung Cancer,"Nsclc, Metastatic",Untreated Advanced Non-Small-Cell Lung Cancer,True,Untreated Advanced Metastatic Non-Small-Cell Lung Cancer,0.98,6,56,2,0.5,False,False,,0.891089109,High,0.891089109,Untreated Advanced Metastatic Non-Small-Cell Lung Cancer
394031,Tropion-Lung07: A Phase III Trial Of Datopotamab Deruxtecan (Dato-Dxd) Plus Pembrolizumab (Pembro) With Or Without Platinum Chemotherapy (Pt-Ct) As First-Line (1L) Therapy In Advanced/Metastatic (Adv/Met) Non-Small Cell Lung Cancer (Nsclc) With Pd-L1 Expression,"Nsclc, Metastatic",First-Line Advanced/Metastatic Non-Small Cell Lung Cancer,True,First-Line Locally Advanced Metastatic PD-L1-Expressing Non-Small Cell Lung Cancer,0.9,9,82,2,0.65,True,False,,1.0,High,1.0,First-Line Locally Advanced Metastatic PD-L1-Expressing Non-Small Cell Lung Cancer
410410,IFNg-Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies,Glomerular Diseases: From Multiomics to Mechanisms,Glomerular Disease,True,APOL1-Expressing Pyroptotic Angiopathy,0.95,3,38,0,0.15,False,False,,0.321428571,Low,0.321428571,APOL1-Expressing Pyroptotic Angiopathy
230186,Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.,Care Delivery and Regulatory Policy,COVID-19 Infection;;Adult Cancer,True,Adult COVID-19;;Adult Cancer,0.98,3,28,1,0.25,True,False,,0.867924528,High,0.867924528,Adult COVID-19;;Adult Cancer
394030,"Harmoni: Randomized, Double-Blind, Multi-Center, Phase III Clinical Study Of Ivonescimab Or Placebo Combined With Pemetrexed And Carboplatin In Patients With Egfr-Mutant Locally Advanced Or Metastatic Non-Squamous Nsclc Who Have Progression Following Egfr-Tki Treatment","Nsclc, Metastatic",EGFR-Mutant Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer,True,Locally Advanced or Metastatic EGFR-Mutated Non-Squamous NSCLC With Progression Following EGFR-TKI Treatment,0.98,12,108,2,0.8,True,False,,0.628019324,Moderate,0.628019324,Locally Advanced or Metastatic EGFR-Mutated Non-Squamous NSCLC With Progression Following EGFR-TKI Treatment
394009,Challenge Of Systemic First-Line Treatment Of Elderly Lung Cancer Patients,"Nsclc, Metastatic",First-Line Elderly Lung Cancer,True,First-Line Elderly Metastatic Nsclc,0.98,4,35,0,0.2,False,False,,0.430769231,Moderate,0.430769231,First-Line Elderly Metastatic Nsclc
295712,The impact of an Education WhatsApp Group to support nurses working in an acute oncology/haematology setting during the Covid-19 pandemic,"Empowering young cancer nurses academically, clinically and in career progression",Covid-19 Infection,True,Cancer;;Hematologic Malignancy,0.6,2,30,1,0.2,False,False,,0.342857143,Low,0.342857143,Cancer;;Hematologic Malignancy
262979,Characteristics And Outcome Of Patients With Acute Promyelocytic Leukemia In Southern Tunisia,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia,True,Acute Promyelocytic Leukemia,1.0,3,28,2,0.35,False,False,,1.0,High,1.0,Acute Promyelocytic Leukemia
262973,Efficacy Of Azacitidine And Venetoclax In Aml Patients May Be Limited By Interactionwith Posaconazole And Lack Of Standardised Treatment Protocol. Real World Data From 3 Major Centres In Singapore.,Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,1.0,3,22,2,0.35,False,False,,1.0,High,1.0,Acute Myeloid Leukemia
181042,Improving Completion Rates of Transcranial Doppler Ultrasounds in Children with Sickle Cell Disease Using Quality Improvement Efforts: In-Clinic Vs. Population-Based Assessments,Health Services Research-Non-Malignant Conditions: Poster I,Childhood Sickle Cell Disease ,True,Childhood Sickle Cell Disease,0.98,4,29,1,0.3,False,False,,1.0,High,1.0,Childhood Sickle Cell Disease
394045,"Camrelizumab Plus Chemotherapy Versus Concurrent Chemoradiotherapy As Neoadjuvant Therapy For Resectable Thoracic Oesophageal Squamous Cell Cancer (Revo): A Multicenter, Randomized, Open-Label, Phase II Trial",Oesophagogastric Cancer,Resectable Thoracic Oesophageal Squamous Cell Cancer ,True,Resectable Thoracic Oesophageal Squamous Cell Cancer,0.99,6,52,1,0.4,False,False,,1.0,High,1.0,Resectable Thoracic Oesophageal Squamous Cell Cancer
213817,"Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer","MP28: Health Services Research: Practice Patterns, Quality of Life and Shared Decision Making III",High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,True,High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,0.98,7,86,1,0.45,False,False,,1.0,High,1.0,High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer
377658,Early Severe Adverse Events Of Acute Myeloid Leukemia Therapy Depending On The Induction Therapy Regimen,Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia ,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,1.0,High,1.0,Acute Myeloid Leukemia
312127,Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis,Ignite Session 8A,Rheumatoid Arthritis,True,Rheumatoid Arthritis,0.95,2,20,0,0.1,False,False,,1.0,High,1.0,Rheumatoid Arthritis
312133,Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation,Ignite Session 8A,Rheumatoid Arthritis,True,Rheumatoid Arthritis;;Acute Inflammation,0.95,3,40,1,0.25,False,False,,0.677966102,Moderate,0.677966102,Rheumatoid Arthritis;;Acute Inflammation
181049,The Telemedicine Experience for Individuals with Sickle Cell Disease,Health Services Research-Non-Malignant Conditions: Poster I,Sickle Cell Disease,True,Sickle Cell Disease,0.98,3,19,1,0.25,False,False,,1.0,High,1.0,Sickle Cell Disease
181055,Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation,Health Services Research-Non-Malignant Conditions: Poster I,Clostridium Difficile Infection,True,Clostridium Difficile Infection in Autologous Stem Cell Transplantation,0.95,8,71,0,0.4,False,False,,0.918918919,High,0.918918919,Clostridium Difficile Infection in Autologous Stem Cell Transplantation
262962,Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia;;Thrombosis,True,High-Risk Acute Promyelocytic Leukemia with Thrombosis,0.95,6,54,2,0.5,False,False,,0.826086957,High,0.826086957,High-Risk Acute Promyelocytic Leukemia with Thrombosis
410433,Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil,Coronavirus (COVID-19),COVID-19 Infection,True,COVID-19,0.75,1,8,0,0.05,True,False,,0.333333333,Low,0.333333333,COVID-19
410436,Comparison of 4 Predictive Scoring Methods as Assessment Tools for Cardiac Surgery Associated-Acute Kidney Injury in Post Coronary Artery Bypass Surgery Patients: A Single-Center Retrospective Study,Acute Kidney Injury,Acute Kidney Injury,True,Post-Coronary Artery Bypass Surgery Acute Kidney Injury,0.98,7,55,1,0.45,False,False,,0.47826087,Moderate,0.47826087,Post-Coronary Artery Bypass Surgery Acute Kidney Injury
181043,Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need,Health Services Research-Non-Malignant Conditions: Poster I,,True,Non-Malignant Hematologic Disorder,0.9,3,34,1,0.25,False,False,,0.971428571,High,0.971428571,Non-Malignant Hematologic Disorder
328516,INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study,Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III,Relapsed/Refractory Myelofibrosis,True,Relapsed or Refractory Myelofibrosis,1.0,4,36,2,0.4,False,False,,0.86746988,High,0.86746988,Relapsed or Refractory Myelofibrosis
295778,Discussion led by Chair,Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
394087,Gut Microbiome And Metabolome Are Associated With The Response To Chemoradiotherapy In Patients With Esophageal Cancer,Oesophagogastric Cancer,Esophageal Cancer,True,Esophageal Cancer,1.0,2,17,1,0.2,False,False,,1.0,High,1.0,Esophageal Cancer
394098,Factors Associated With Uptake Of Adjuvant Nivolumab In A Nationwide Esophageal Cancer Patient Cohort,Oesophagogastric Cancer,Esophageal Cancer,True,Esophageal Cancer,1.0,2,17,1,0.2,False,False,,1.0,High,1.0,Esophageal Cancer
295765,Can the molecular classification guide adjuvant medical treatment?,What is the optimal therapeutic approach in high-risk endometrial cancer?,High-Risk Endometrial Cancer,True,High-Risk Endometrial Cancer,0.98,3,28,1,0.25,False,False,,1.0,High,1.0,High-Risk Endometrial Cancer
181083,"Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)",Health Services Research-Lymphoid Malignancies: Poster I,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.98,3,28,2,0.35,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia
344918,b-Escin eradicates cancer stem-like population in HER2-positive breast cancer with trastuzumab resistance,Drug Resistance in Molecular Targeted Therapies 2,HER2-Positive Breast Cancer,True,Trastuzumab-Resistant HER2-Positive Breast Cancer,0.98,4,49,3,0.5,False,False,,0.710526316,High,0.710526316,Trastuzumab-Resistant HER2-Positive Breast Cancer
410465,A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,Acute Kidney Injury,ANCA-Mediated Acute Interstitial Nephritis,True,ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,0.98,6,69,1,0.4,True,False,,0.756756757,High,0.756756757,ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis
263003,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia with T(6;9)(P22;Q34),0.98,5,43,2,0.45,False,True,,1.0,High,1.0,Acute Myeloid Leukemia with T(6;9)(P22;Q34)
344908,"PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma",Drug Resistance in Molecular Targeted Therapies 2,Melanoma,True,Melanoma,0.9,1,8,0,0.05,False,False,,1.0,High,1.0,Melanoma
295775,Management of treatment-related neurological complications,"Management of brain metastases: Systemic treatment, radiosurgery or both?",Brain Metastasis,True,Treatment-Related Neurological Complication,0.95,3,43,1,0.25,False,False,,0.988505747,High,0.988505747,Treatment-Related Neurological Complication
410466,AKI and Spontaneous Rupture of the Urinary Collecting System,Acute Kidney Injury,Acute Kidney Injury,True,Acute Kidney Injury and Spontaneous Rupture of the Urinary Collecting System,0.98,11,76,1,0.65,False,False,,0.972972973,High,0.972972973,Acute Kidney Injury and Spontaneous Rupture of the Urinary Collecting System
295751,Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study,"Proffered Paper session 2: GI, lower digestive",BRAF V600E-Mutated Metastatic Colorectal Cancer,True,Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer,0.98,7,65,2,0.55,True,False,,0.828828829,High,0.828828829,Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer
181105,Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations,Outcomes Research-Non-Malignant Conditions: Poster I,Pediatric Sickle Cell Disease,True,Pediatric Sickle Cell Disease with Vaso-Occlusive Events,0.98,7,56,1,0.45,False,False,,0.682352941,Moderate,0.682352941,Pediatric Sickle Cell Disease with Vaso-Occlusive Events
213839,Aquablation in very large prostates (>150mL): technique and multicenter case series,MP29: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia with Very Large Prostates (>150mL),0.98,8,63,0,0.4,False,True,,0.991735537,High,0.991735537,Benign Prostatic Hyperplasia with Very Large Prostates (>150mL)
148309,Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis,Myeloproliferative Neoplasms - Clinical,Primary Myelofibrosis,True,Overt Primary Myelofibrosis,0.95,3,27,0,0.15,False,False,,0.617647059,Moderate,0.617647059,Overt Primary Myelofibrosis
394135,Integrated Palliative Care For Patients Referred For Chimeric Antigen Receptor T-Cell (Car-T) Therapy: A Service Evaluation,Palliative Care,,True,,1.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
312224,Alarcon's NETting Neutrophils,Knowledge Bowl Preliminary Round,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
164756,High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis,Updates in Mycobacteria,Tuberculous Meningitis,True,TB Meningitis,1.0,2,13,0,0.1,True,False,,0.742857143,High,0.742857143,TB Meningitis
344966,Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer,New Drug Targets,High Grade Serous Ovarian Cancer,True,High Grade Serous Ovarian Cancer,1.0,5,32,2,0.45,False,False,,1.0,High,1.0,High Grade Serous Ovarian Cancer
344993,Sex differences in the innate immune response to lung cancer,Innate Immunity to Tumors,Lung Cancer,True,Lung Cancer,0.98,2,11,1,0.2,False,False,,1.0,High,1.0,Lung Cancer
377741,Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant Is An Effective Consolidative Strategy For High-Risk Acute Myeloid Leukaemia And Myelodysplastic Syndrome,Stem cell transplantation - Clinical,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome,True,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome,0.98,6,69,2,0.5,False,False,,1.0,High,1.0,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome
263060,Burkitt Lymphoma International Prognostic Index (Bl-Ipi): Is It Efficient Enough In Adult Burkitt Lymphoma Patients?,Aggressive Non-Hodgkin lymphoma - Clinical,Adult Burkitt Lymphoma,True,Adult Burkitt Lymphoma,0.98,3,22,1,0.25,False,False,,1.0,High,1.0,Adult Burkitt Lymphoma
295814,Stepping into the emerging needs in metastatic breast cancer,Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer,Metastatic Breast Cancer,True,"Metastatic Triple-Negative Breast Cancer;; Metastatic HR-Positive, HER2-Negative Breast Cancer",0.98,9,94,3,0.75,True,False,,0.417391304,Moderate,0.417391304,"Metastatic Triple-Negative Breast Cancer;; Metastatic HR-Positive, HER2-Negative Breast Cancer"
181112,Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center,Outcomes Research-Non-Malignant Conditions: Poster I,Sars-Cov-2- Pneumonia,True,Sars-Cov-2- Pneumonia;;Viral Pneumonia,0.98,3,38,0,0.15,False,False,,0.714285714,High,0.714285714,Sars-Cov-2- Pneumonia;;Viral Pneumonia
181110,Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease Using the Pittsburgh Sleep Quality Index,Outcomes Research-Non-Malignant Conditions: Poster I,Adolescent Young Adult Sickle Cell Disease,True,Adolescent Sickle Cell Disease;;Young Adult Sickle Cell Disease,0.98,8,63,1,0.5,False,False,,1.0,High,1.0,Adolescent Sickle Cell Disease;;Young Adult Sickle Cell Disease
263044,No Impact Of Statin Use On Response And Survival Rates In Newly Diagnosed Dlbcl Patients Treated With R-Da-Epoch,Aggressive Non-Hodgkin lymphoma - Clinical,Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,Newly Diagnosed Diffuse Large B-Cell Lymphoma,0.98,6,45,2,0.5,False,False,,1.0,High,1.0,Newly Diagnosed Diffuse Large B-Cell Lymphoma
164735,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,The Interplay Between COVID and other Infections,,True,Bloodborne Pathogen Exposure;; COVID-19,0.85,4,39,0,0.2,True,False,,0.777777778,High,0.777777778,Bloodborne Pathogen Exposure;; COVID-19
181114,Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease,Outcomes Research-Non-Malignant Conditions: Poster I,Sickle Cell Disease;;Venous Thromboembolism,True,Post-COVID-19 Venous Thromboembolism with Sickle Cell Disease,0.98,7,61,1,0.45,True,False,,0.966666667,High,0.966666667,Post-COVID-19 Venous Thromboembolism with Sickle Cell Disease
263082,Zanubrutinib In Combination With Lenalidomide And Rituximab Versus R-Minichop In Unfit Or Frail Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Aged Over Or Equal To 70 Years,Aggressive Non-Hodgkin lymphoma - Clinical,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,Newly Diagnosed Elderly Unfit or Frail Diffuse Large B-Cell Lymphoma,0.98,10,68,2,0.7,False,False,,0.857142857,High,0.857142857,Newly Diagnosed Elderly Unfit or Frail Diffuse Large B-Cell Lymphoma
377743,Inotuzumab Ozogamicin Treatment In Adult Patients With Relapsed Or Refractory Philadelphia Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life French Study,Acute lymphoblastic leukemia - Clinical,Adult Relapsed Or Refractory Ph-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,True,Adult Relapsed or Refractory Ph Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,1.0,12,111,6,1.0,False,False,,0.544117647,Moderate,0.544117647,Adult Relapsed or Refractory Ph Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
394195,Diagnostic Performance Of Blood-Based Dna Methylation Assay Using Epigenetic-Specific Peptide Nucleic Acid In Pancreatic Adenocarcinoma,Pancreatic Cancer,Pancreatic Adenocarcinoma,True,Pancreatic Adenocarcinoma,1.0,2,25,1,0.2,False,False,,1.0,High,1.0,Pancreatic Adenocarcinoma
328644,Validation of a Novel Algorithm with a High Specificity in Ruling out MDS,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster III,Myelodysplastic Syndrome,True,Myelodysplastic Syndromes,0.98,2,25,1,0.2,False,False,,1.0,High,1.0,Myelodysplastic Syndromes
148407,Gbt021601 Improves The Pathophysiology Of Sickle Cell Disease In A Murine Model,Sickle Cell Disease,Sickle Cell Disease,True,Sickle Cell Disease,1.0,3,19,1,0.25,False,False,,1.0,High,1.0,Sickle Cell Disease
345045,Targeting CD73-adenosine axis for the treatment of multiple myeloma,Novel Antitumor Agents 1,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
394187,Clinical And Molecular Features Of Young Onset Pancreatic Adenocarcinoma,Pancreatic Cancer,Young Onset Pancreatic Adenocarcinoma,True,Young Onset Pancreatic Adenocarcinoma,1.0,4,37,1,0.3,False,False,,1.0,High,1.0,Young Onset Pancreatic Adenocarcinoma
345049,Serological responses to tumor-associated adducts in pancreatic cancer,Adaptive Immunity to Tumors,Pancreatic Cancer,True,Pancreatic Cancer,0.98,2,17,1,0.2,False,False,,1.0,High,1.0,Pancreatic Cancer
213966,Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder - A Claims Database Analysis,"MP35: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I",Hypoactive Sexual Desire Disorder,True,Female Hypoactive Sexual Desire Disorder,0.98,5,40,1,0.35,False,False,,1.0,High,1.0,Female Hypoactive Sexual Desire Disorder
230358,Assessment of neurocognitive functions using ACE-III scale in patients with high-grade glioma receiving adjuvant chemoradiation.,Central Nervous System Tumors,High-Grade Glioma,True,High Grade Glioma,0.98,3,17,1,0.25,False,False,,1.0,High,1.0,High Grade Glioma
345008,POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy,Targeting Replication Stress and the Immune Microenvironment,,True,POLE-Mutated Solid Tumor,0.85,3,24,1,0.25,True,False,,0.0,Low,0.0,POLE-Mutated Solid Tumor
181176,Identification of Small Molecules That Induce Therapeutic Levels of Fetal Hemoglobin for Treatment of Sickle Cell Disease By Pairing Machine Learning with High-Resolution Single Cell RNA Sequencing Maps of Adult and Fetal Human Erythropoiesis,"Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II",Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,1.0,High,1.0,Sickle Cell Disease
230361,The effects of vascular endothelial cells on regulating post-irradiation microglia phenotype in irradiation-induced brain injury.,Central Nervous System Tumors,Brain Injury,True,Irradiation-Induced Brain Injury,0.98,3,32,0,0.15,False,False,,0.967741935,High,0.967741935,Irradiation-Induced Brain Injury
295865,Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer,"Mini Oral session: GI, lower digestive",Resected Stage I-III Colorectal Cancer,True,Resected Stage 1-3 Colorectal Cancer,0.98,5,36,2,0.45,False,False,,1.0,High,1.0,Resected Stage 1-3 Colorectal Cancer
230348,"Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.",Central Nervous System Tumors,Grade 2 Grade 3 Central Nervous System Tumor,True,Grade II Glioma;;Grade III Glioma,0.98,5,33,1,0.35,True,False,,1.0,High,1.0,Grade II Glioma;;Grade III Glioma
148434,Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation,Stem Cell Transplantation - Clinical,11Q23 Rearranged Acute Leukemia,True,MRD-Positive 11q23-Rearranged Acute Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplantation,0.98,9,100,3,0.75,True,False,,0.901098901,High,0.901098901,MRD-Positive 11q23-Rearranged Acute Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplantation
312263,Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field,Moving on Up: Changing How We Define Early Knee OA and Get People Moving,Osteoarthritis ,True,Osteoarthritis;;At Risk for Osteoarthritis,0.95,4,42,0,0.2,False,False,,0.948717949,High,0.948717949,Osteoarthritis;;At Risk for Osteoarthritis
213982,The effect of renal transplantation on erectile functions in patients with end-stage renal disease.,MP36: Renal Transplantation & Vascular Surgery,End-Stage Renal Disease,True,End Stage Renal Disease,0.99,4,23,2,0.4,False,False,,1.0,High,1.0,End Stage Renal Disease
377819,Characterisation Of Quality Of Life-Linked Patient-Reported Outcomes Through A Digital And Continuous Remote Monitoring Ecosystem In Sickle Cell Disease.,Sickle cell disease,Sickle Cell Disease,True,Sickle Cell Disease,1.0,3,19,1,0.25,False,False,,1.0,High,1.0,Sickle Cell Disease
213989,Pilot Trial for PIVoT: Prevention of recurrent urinary tract Infection using Vaginal Testosterone,MP37: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia,Recurrent Urinary Tract Infection,True,Recurrent Urinary Tract Infection,0.99,4,33,0,0.2,False,False,,1.0,High,1.0,Recurrent Urinary Tract Infection
328676,The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster I,Myelodysplastic Syndrome,True,Myelodysplastic Syndrome,0.98,2,24,1,0.2,False,False,,0.631578947,Moderate,0.631578947,Myelodysplastic Syndrome
181218,Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,B-Cell Lymphoma,True,B-Cell Lymphoma,0.98,2,15,1,0.2,False,False,,0.612244898,Moderate,0.612244898,B-Cell Lymphoma
263163,Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort,"Enzymopathies, membranopathies and other anemias",Systemic Sclerosis,True,Anemia In Systemic Sclerosis,0.98,4,28,0,0.2,False,False,,1.0,High,1.0,Anemia In Systemic Sclerosis
213985,Robotic Bilateral Nephrectomy for Large Kidneys with Adult Polycystic Kidney Disease with Da Vinci Xi and Da Vinci SP,MP36: Renal Transplantation & Vascular Surgery,Adult Polycystic Kidney Disease,True,Adult Polycystic Kidney Disease with Large Kidneys,0.98,7,50,1,0.45,False,False,,1.0,High,1.0,Adult Polycystic Kidney Disease with Large Kidneys
181215,Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure,"Granulocytes, Monocytes, and Macrophages: Poster II",Pediatric Primary Hemophagocytic Lymphohistiocytosis,True,Pediatric Primary Hemophagocytic Lymphohistiocytosis (HLH),0.98,5,58,0,0.25,True,True,,0.962962963,High,0.962962963,Pediatric Primary Hemophagocytic Lymphohistiocytosis (HLH)
214013,"Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction after Discontinuation of Finasteride",MP38: Sexual Function/Dysfunction: Basic Research & Pathophysiology,Sexual Dysfunction,True,Persistent Sexual Dysfunction,0.98,3,29,0,0.15,False,False,,1.0,High,1.0,Persistent Sexual Dysfunction
295910,Discussion led by Chair,How can we use ctDNA for early detection of cancer?,Cancer,True,Cancer,0.85,1,6,1,0.15,False,False,,1.0,High,1.0,Cancer
295920,Systemic therapeutic options,Oligometastatic disease and oligoprogression in breast cancer,Oligometastatic Disease;;Breast Cancer,True,Oligometastatic Breast Cancer;; Oligoprogressive Breast Cancer,0.98,6,62,1,0.4,False,False,,1.0,High,1.0,Oligometastatic Breast Cancer;; Oligoprogressive Breast Cancer
410619,A Rare Case of Zonisamide-Induced Distal Renal Tubular Acidosis (RTA),"Fluid, Electrolytes, and Acid-Base Disorders",Distal Renal Tubular Acidosis,True,Zonisamide-Induced Distal Renal Tubular Acidosis (RTA),0.99,6,54,0,0.3,True,True,,0.716049383,High,0.716049383,Zonisamide-Induced Distal Renal Tubular Acidosis (RTA)
263162,The Value Of Anemia For Organ Damage Evaluation In Systemic Sclerosis Patients:A Multi-Center Retrospective Study,"Enzymopathies, membranopathies and other anemias",Systemic Sclerosis,True,Systemic Sclerosis With Anemia,0.98,4,30,0,0.2,False,False,,0.75,High,0.75,Systemic Sclerosis With Anemia
410621,Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia,"Fluid, Electrolytes, and Acid-Base Disorders",Severe Hyponatremia,True,Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia,0.98,3,60,1,0.25,False,False,,0.481012658,Moderate,0.481012658,Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia
181219,Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,True,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorders,0.9,5,73,1,0.35,False,False,,0.993006993,High,0.993006993,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorders
312364,Balancing Risks and Benefits of Adding Immunosuppression to Steroids in PMR,Polymyalgia Rheumatica: New Tricks for an Old Disease,Polymyalgia Rheumatica,True,Polymyalgia Rheumatica,1.0,2,22,0,0.1,False,False,,1.0,High,1.0,Polymyalgia Rheumatica
312341,"Red but White, Itchy but Painful, Controlled yet Uncontrolled",Pediatric Thieves Market Poster,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
312328,A Perplexing Situation,Pediatric Thieves Market Poster,,True,,0.1,0,0,0,0.0,False,False,,0.0,Low,0.0,
394242,Young Adult Lung Cancer Demands More Attention In A Low-Resource Area: Bangladesh Perspective,Policy And Preventive Strategies,Young Adult Lung Cancer,True,Young Adult Lung Cancer,1.0,4,23,1,0.3,False,False,,1.0,High,1.0,Young Adult Lung Cancer
181258,"Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)",Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II,Severe Von Willebrand Disease,True,Severe Von Willebrand Disease,0.99,4,29,2,0.4,False,False,,1.0,High,1.0,Severe Von Willebrand Disease
328700,Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eu-TCL1 Murine Model,Chronic Lymphocytic Leukemias: Basic and Translational: Poster II,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.98,3,28,2,0.35,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia
328712,High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemias: Basic and Translational: Poster III,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.98,3,28,2,0.35,False,False,,1.0,High,1.0,Chronic Lymphocytic Leukemia
345103,Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions,Cancer-associated Inflammation and Microbiome,Renal Cell Carcinoma,True,Metastatic Renal Cell Carcinoma,0.98,4,31,1,0.3,False,False,,1.0,High,1.0,Metastatic Renal Cell Carcinoma
148508,Possible Correlation Of Mixed Chimerism With Post-Transplant Outcome In Patients With B Thalassemia:Risk Of Graft Failure,Thalassemias,B Thalassemia,True,B Thalassemia with Mixed Chimerism,0.9,5,34,0,0.25,False,False,,0.957746479,High,0.957746479,B Thalassemia with Mixed Chimerism
263205,First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.,Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,First-Line Advanced Stage Folicular Lymphoma,True,First-Line Advanced Stage Follicular Lymphoma,0.98,5,45,3,0.55,False,False,,1.0,High,1.0,First-Line Advanced Stage Follicular Lymphoma
377875,Alloantibodies In Von Willebrand Disease: About 6 Cases In Southern Tunisia,Bleeding disorders (congenital and acquired),Von Willebrand Disease,True,Von Willebrand Disease With Alloantibodies,0.95,5,42,1,0.35,False,False,,0.511627907,Moderate,0.511627907,Von Willebrand Disease With Alloantibodies
394296,Impact Of Intensified Androgen Deprivation Therapy (Adti) In The Metastatic Castration-Sensitive Prostate Cancer (Mcspc) Setting On Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Disease Characteristics And Survival Outcomes,Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer,True,Metastatic Castration-Sensitive Prostate Cancer;; Metastatic Castration-Resistant Prostate Cancer,0.98,8,97,2,0.6,False,False,,1.0,High,1.0,Metastatic Castration-Sensitive Prostate Cancer;; Metastatic Castration-Resistant Prostate Cancer
295985,Welcome and Introduction,Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients,HR-Positive HER2 Advanced Breast Cancer,True,Advanced HR+/HER2- Breast Cancer,0.98,4,32,2,0.4,True,False,,0.769230769,High,0.769230769,Advanced HR+/HER2- Breast Cancer
328738,The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia with Covid-19,0.9,5,42,2,0.45,False,False,,0.608695652,Moderate,0.608695652,Chronic Lymphocytic Leukemia with Covid-19
410659,External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis,Geriatric Nephrology,,True,Elderly Initiated On Dialysis,0.85,4,29,0,0.2,False,False,,1.0,High,1.0,Elderly Initiated On Dialysis
328806,Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
345167,Integrin-mediated lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia,Cancer Cachexia,Cancer-Associated Cachexia,True,Pancreatic Cancer-Associated Cachexia,0.98,3,37,1,0.25,False,False,,1.0,High,1.0,Pancreatic Cancer-Associated Cachexia
345147,Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing,Innovative Approaches for Tumor Profiling and Data Analysis 1,Ovarian Cancer,True,BRCA-Mutated Ovarian Cancer,1.0,3,27,1,0.25,True,False,,1.0,High,1.0,BRCA-Mutated Ovarian Cancer
263249,Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas,Lymphoma Biology & Translational Research,B-Cell Lymphoma,True,Tp53-Mutated B-Cell Lymphoma,0.98,3,28,1,0.25,False,False,,1.0,High,1.0,Tp53-Mutated B-Cell Lymphoma
263250,"Surgical Specimens Of Indolent And Aggressive B-Nhls Show Differences In Their Flow-Cytometry Profile Of Ploidy, Proliferating Fraction And Proportion Of Tumor-Associated Myeloid And T-Cell Subsets",Lymphoma Biology & Translational Research,Indolent Aggressive B-cell non-Hodgkin lymphoma,True,Indolent B-cell Non-Hodgkin Lymphoma;;Aggressive B-cell Non-Hodgkin Lymphoma,0.98,7,76,1,0.45,False,False,,1.0,High,1.0,Indolent B-cell Non-Hodgkin Lymphoma;;Aggressive B-cell Non-Hodgkin Lymphoma
148549,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,Transfusion Medicine,,True,Red Blood Cell Autoantibodies with Thrombotic Risk,0.95,7,50,0,0.35,False,False,,1.0,High,1.0,Red Blood Cell Autoantibodies with Thrombotic Risk
410696,Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure,Glomerular Diseases,Late-Onset Lupus Nephritis,True,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure,0.98,7,61,1,0.45,False,False,,0.604651163,Moderate,0.604651163,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure
410708,Porphyria Cutanea Tarda and Systemic Lupus Erythematosus: An Unusual Association in a Patient with Nephritic Syndrome,Glomerular Diseases,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,True,Porphyria Cutanea Tarda and Systemic Lupus Erythematosus with Nephritic Syndrome,0.98,10,80,1,0.6,False,False,,0.7,Moderate,0.7,Porphyria Cutanea Tarda and Systemic Lupus Erythematosus with Nephritic Syndrome
279637,Managing relapsed/refractory mantle cell lymphoma: a case study,Gilead and Kite Oncology: Chimeric antigen receptor T cells case studies: navigating patient management,Relapsed/Refractory Mantle Cell Lymphoma,True,Relapsed/Refractory Mantle Cell Lymphoma,0.98,4,40,3,0.5,False,False,,0.792079208,High,0.792079208,Relapsed/Refractory Mantle Cell Lymphoma
181344,Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia,Bone Marrow Failure: Poster II,Adult Severe Aplastic Anemia,True,Adult Severe Aplastic Anemia,0.98,4,28,1,0.3,False,False,,1.0,High,1.0,Adult Severe Aplastic Anemia
263238,Protection Of Patients With Hematologic Malignancy From Severe Infection During Pandemia: Estonian Two Centres Experience,Infections in hematology (incl. supportive care/therapy),Hematologic Malignancy,True,Hematologic Malignancy;;Severe Infection,0.98,3,40,1,0.25,False,False,,0.543209877,Moderate,0.543209877,Hematologic Malignancy;;Severe Infection
377920,Atypical Chronic Myeloid Leukemia (Acml) And Autoimmune Disease: Report Of Two Cases.,Myeloproliferative neoplasms - Clinical,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,True,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,0.98,5,53,3,0.55,False,False,,0.95412844,High,0.95412844,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease
410725,Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis,"Health Maintenance, Nutrition, and Metabolism",,True,Malnutrition;;End Stage Renal Disease;;Congenital Heart Disease,0.95,6,63,2,0.5,False,False,,0.880733945,High,0.880733945,Malnutrition;;End Stage Renal Disease;;Congenital Heart Disease
164938,Infectious Complications of CD19-targeted Chimeric Antigen Receptor-modified T (CAR-T)-cell Immunotherapy,ID Complications associated with Novel Cellular & Immunotherapies in Cancer,Cancer,True,CD19-positive Cancer,0.9,2,20,2,0.3,False,False,,0.279569892,Low,0.279569892,CD19-positive Cancer
148578,L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia - Clinical,Childhood Acute Pancreatitis;;Acute Lymphoblastic Leukemia,True,Childhood Acute Lymphoblastic Leukemia;;Childhood Acute Pancreatitis,0.98,6,68,2,0.5,False,False,,0.567164179,Moderate,0.567164179,Childhood Acute Lymphoblastic Leukemia;;Childhood Acute Pancreatitis
312429,Wrap-Up,Review Course,,True,,0.0,0,0,0,0.0,False,False,,0.0,Low,0.0,
197778,Mitochondrial Interventions: Small Molecule and Gene Therapy,Mitochondrial Interventions: Small Molecule and Gene Therapy (Mitochondrial Interventions: Small Molecule and Gene Therapy),,True,,0.1,0,0,0,0.0,False,False,,0.0,Low,0.0,
345225,Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",Breast Cancer,True,Breast Cancer,0.98,2,13,1,0.2,False,False,,1.0,High,1.0,Breast Cancer
345226,Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",,True,,0.95,0,0,0,0.0,False,False,,0.0,Low,0.0,
263309,Crispr-Cas9 Knockout Screen Identifies Rna Modification Enzymes Essential For Cell Survival In Multiple Myeloma,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
230538,Comparative oncology analysis using genomic profiling of canine cancers by tissue and liquid biopsy testing reveals actionable somatic alterations with orthologs in human cancers.,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Cancer,True,Cancer,0.6,1,6,1,0.15,False,False,,1.0,High,1.0,Cancer
296059,"Cosmesis (CA), late effects (LE) and Patient reported outcome measures (PROM) in high risk breast cancer (BC) treated with hypo-fractionated radiotherapy (RT): real world outcome from a developing country.","Breast cancer, early stage",High Risk Breast Cancer ,True,Early Stage High-Risk Breast Cancer,0.98,5,35,3,0.55,False,False,,0.793103448,High,0.793103448,Early Stage High-Risk Breast Cancer
296081,Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal Cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER,Colorectal cancer,HER2-Positive Metastatic Colorectal Cancer,True,Metastatic HER2-positive Colorectal Cancer,0.98,4,42,2,0.4,False,False,,1.0,High,1.0,Metastatic HER2-positive Colorectal Cancer
394376,Adjuvant Everolimus (Eve) In Patients (Pts) With Completely Resected Very High-Risk Renal Cell Cancer (Rcc) And Clear Cell Histology: Results From The Phase Iii Swog S0931 (Everest) Trial,Renal Cancer,Resected Very High-Risk Renal Cell Cancer,True,Resected Very High-Risk Clear Cell Renal Cell Cancer,0.98,8,52,1,0.5,False,False,,1.0,High,1.0,Resected Very High-Risk Clear Cell Renal Cell Cancer
296084,"The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer - the randomized NORDIC9-study",Colorectal cancer,Elderly Metastatic Colorectal Cancer,True,Vulnerable Elderly Metastatic Colorectal Cancer,0.98,5,47,1,0.35,False,False,,0.86746988,High,0.86746988,Vulnerable Elderly Metastatic Colorectal Cancer
214129,MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis,MP45: Prostate Cancer: Markers,Prostate Cancer,True,Low-Risk Prostate Cancer,0.98,3,24,1,0.25,False,False,,1.0,High,1.0,Low-Risk Prostate Cancer
165004,The Impact of Molecular Diagnostics on the Management of Viral Infections in Pediatric Transplant Recipients,Controversies and Challenges in Pediatric Transplant ID,Pediatric Viral Infection,True,Pediatric Viral Infection in Transplant Recipients,0.98,6,50,0,0.3,False,False,,1.0,High,1.0,Pediatric Viral Infection in Transplant Recipients
296071,Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: a phase II clinical trial (NeoBCC),Melanoma and other skin tumours,Primary Basal Cell Carcinoma,True,Difficult to Resect Primary Basal Cell Carcinoma,0.98,7,48,1,0.45,False,False,,1.0,High,1.0,Difficult to Resect Primary Basal Cell Carcinoma
296082,A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration,"NSCLC, metastatic",Lung Disease,True,First-Line Metastatic Non-Small Cell Lung Cancer,0.95,6,48,1,0.4,False,False,,1.0,High,1.0,First-Line Metastatic Non-Small Cell Lung Cancer
263312,"Trial-In-Progress: Phase Ii Study Of Phe885, A B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, In Adults With Relapsed And/Or Refractory Multiple Myeloma",Myeloma and other monoclonal gammopathies - Clinical,Adult Relapsed/Refractory Multiple Myeloma,True,Adult Relapsed/Refractory Multiple Myeloma,0.98,4,42,3,0.5,False,False,,0.661417323,Moderate,0.661417323,Adult Relapsed/Refractory Multiple Myeloma
345240,"CRB-601, an avb8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment","Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",,True,,0.2,0,0,0,0.0,False,False,,0.0,Low,0.0,
181422,The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II,B-Cell Lymphoma,True,B-Cell Lymphoma,1.0,2,15,1,0.2,False,False,,1.0,High,1.0,B-Cell Lymphoma
230572,A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.,Gastrointestinal Cancer-Colorectal and Anal,Metastatic Colorectal Cancer,True,Metastatic Colorectal Cancer,1.0,3,28,1,0.25,False,False,,1.0,High,1.0,Metastatic Colorectal Cancer
165030,To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings,The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention,COVID-19 Infection,True,Pediatric COVID-19,0.98,2,18,0,0.1,True,False,,1.0,High,1.0,Pediatric COVID-19
312472,A New Classification of Ear Chondritis Revealed by Genetic Studies,The Ears Have It: Autoimmune Hearing Loss and Relapsing Polychondritis,Ear Chondritis,True,Ear Chondritis,0.98,2,14,0,0.1,False,False,,1.0,High,1.0,Ear Chondritis
148649,Dose-Adjusted Edoch-Rituximab In Elderly Patients With High Grade Diffuse Large B-Cell Lymphoma,Aggressive Non-Hodgkin Lymphoma - Clinical,Elderly High Grade Diffuse Large B-Cell Lymphoma,True,Elderly High Grade Diffuse Large B-Cell Lymphoma,0.98,7,48,2,0.55,False,False,,1.0,High,1.0,Elderly High Grade Diffuse Large B-Cell Lymphoma
263316,Chemo Or Chemo-Free Regimens In Heavily Pretreated Multiple Myeloma? Role Of Bendamustine-Bortezomib-Dexamethasone (Bvd) In Novel Agents' Era,Myeloma and other monoclonal gammopathies - Clinical,Heavily Pretreated Multiple Myeloma,True,Heavily Pretreated Multiple Myeloma,0.98,4,35,1,0.3,False,False,,1.0,High,1.0,Heavily Pretreated Multiple Myeloma
296109,Early mortality in patients with cancer treated with immunotherapy in routine practice,Investigational immunotherapy,Cancer,True,Previously Treated Cancer,0.95,3,25,2,0.35,False,False,,0.679245283,Moderate,0.679245283,Previously Treated Cancer
296096,"DeLLphi-303: phase 1b first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)",SCLC,Extensive Stage Small Cell Lung Cancer ,True,First-Line Extensive Stage Small Cell Lung Cancer,0.98,7,49,2,0.55,False,False,,1.0,High,1.0,First-Line Extensive Stage Small Cell Lung Cancer
328871,Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I,Multiple Myeloma,True,Bortezomib Resistant Multiple Myeloma,0.98,4,37,2,0.4,False,False,,1.0,High,1.0,Bortezomib Resistant Multiple Myeloma
148636,Health-Related Quality Of Life Effect Of Mogamulizumab By Patient Blood Involvement,Aggressive Non-Hodgkin Lymphoma - Clinical,Aggressive Non-Hodgkin Lymphoma,True,Aggressive Non-Hodgkin Lymphoma with Blood Involvement,0.95,6,54,1,0.4,False,False,,0.729411765,High,0.729411765,Aggressive Non-Hodgkin Lymphoma with Blood Involvement
263328,Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment,Myeloma and other monoclonal gammopathies - Clinical,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma with Dialysis-Dependent Renal Impairment,0.98,8,73,2,0.6,False,False,,1.0,High,1.0,Newly Diagnosed Multiple Myeloma with Dialysis-Dependent Renal Impairment
410777,Ravulizumab De Novo in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS): First Worldwide Cases,Pediatric Nephrology,De Novo Pediatric Atypical Hemolytic Uremic Syndrome,True,De Novo Pediatric Atypical Hemolytic Uremic Syndrome,0.98,7,52,1,0.45,False,False,,0.916666667,High,0.916666667,De Novo Pediatric Atypical Hemolytic Uremic Syndrome
148631,Relationship Between Genetic Aberrations In The 17P13/Tp53 Locus And Immunohistochemical Protein P53 Expression In Tumor Cells Of Diffuse Large B-Cell Lymphoma,Aggressive Non-Hodgkin Lymphoma - Clinical,Diffuse Large B-Cell Lymphoma,True,Aggressive Diffuse Large B-Cell Lymphoma,0.9,5,40,1,0.35,False,False,,0.84057971,High,0.84057971,Aggressive Diffuse Large B-Cell Lymphoma
148651,"Front-Mind: A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy And Safety Of R-Chop + Tafasitamab + Lenalidomide Vs R-Chop Alone For Newly-Diagnosed High-Risk Dlbcl",Aggressive Non-Hodgkin Lymphoma - Clinical,Newly-Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,True,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,0.98,7,55,2,0.55,False,False,,1.0,High,1.0,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
197852,Accelerated Brain Aging is Independently Associated with Increased Likelihood of All-Cause Mortality: Findings from the Second Wave of Dallas Heart Study (DHS-2),Accelerated Brain Aging in Neuropsychiatric Disorders: Methodological Challenges and and Potential Applications to Prognosticate Clinical Outcomes,Neuropsychiatric Disorder,True,Accelerated Brain Aging,0.95,3,23,0,0.15,False,False,,1.0,High,1.0,Accelerated Brain Aging
181452,Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",Ph-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,1.0,5,51,3,0.55,False,False,,1.0,High,1.0,Ph Chromosome-Positive Acute Lymphoblastic Leukemia
230619,Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.,Gastrointestinal Cancer-Colorectal and Anal,Early-Onset Colorectal Cancer,True,Early Onset Colorectal Cancer,1.0,4,29,2,0.4,False,False,,1.0,High,1.0,Early Onset Colorectal Cancer
279766,Current challenges for patient management,Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID, COVID;;Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
328928,Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
148656,Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center,Bleeding Disorders (Congenital And Acquired),Mild Haemophilia A,True,Mild Haemophilia A,0.98,3,18,1,0.25,False,False,,1.0,High,1.0,Mild Haemophilia A
378058,Tailoring treatment in CLL: Selecting the right treatment and duration for the right patient in relapse setting,You have a new match! Pairing treatments and patients together for optimal treatment in chronic lymphocytic leukaemia (CLL),Chronic Lymphocytic Leukemia,True,Relapsed Chronic Lymphocytic Leukaemia,0.98,4,38,2,0.4,False,False,,1.0,High,1.0,Relapsed Chronic Lymphocytic Leukaemia
263373,"Primary Myelofibrosis In Young Patients <=50 Years: Clinicopathological Characteristics, Genetic Landscape And Disease Outcome. A Single Center Experience",Myeloproliferative neoplasms - Clinical,Adult Primary Myelofibrosis,True,Primary Myelofibrosis,0.98,2,21,0,0.1,False,False,,1.0,High,1.0,Primary Myelofibrosis
214230,Implications of Positive Surgical Margins following Robotic Partial Nephrectomy,MP50: Kidney Cancer: Localized: Surgical Therapy III,Kidney Cancer,True,Localized Kidney Cancer with Positive Surgical Margins,0.98,7,54,2,0.55,False,False,,1.0,High,1.0,Localized Kidney Cancer with Positive Surgical Margins
230598,Clinical and prognostic features of BRAF V600E-mutant resectable colorectal cancer: A single-center retrospective analysis of Chinese patients.,Gastrointestinal Cancer-Colorectal and Anal,BRAF V600E-mutated Resectable Colorectal Cancer,True,BRAF V600E-Mutant Resectable Colorectal Cancer,0.98,5,46,1,0.35,True,False,,0.760869565,High,0.760869565,BRAF V600E-Mutant Resectable Colorectal Cancer
181453,A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",MRD-Positive B-Cell Acute Lymphoblastic Leukemia,True,MRD-Positive B-Cell Acute Lymphoblastic Leukemia,0.98,5,48,3,0.55,True,False,,1.0,High,1.0,MRD-Positive B-Cell Acute Lymphoblastic Leukemia
148685,Clinical Features Of Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia: Results From A Single Center In China,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,True,Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia,0.98,8,68,1,0.5,False,False,,1.0,High,1.0,Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia
214197,When Node-Positive Prostate Cancer Should Be Considered A Systemic Disease? Assessing The Prognostic Role Of Preoperative 68Ga-PSMA PET/CT Results In Patients With Lymph Node Invasion At Final Pathology,MP48: Prostate Cancer: Advanced (including Drug Therapy) III,Node-Positive Prostate Cancer,True,Node-Positive Advanced Prostate Cancer,0.98,4,38,3,0.5,False,False,,0.865671642,High,0.865671642,Node-Positive Advanced Prostate Cancer
279755,How should Measurable Residual Disease (MRD) assessment inform treatment decisions?,Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?,High-Risk Acute Myeloid Leukemia,True,High-Risk Acute Myeloid Leukaemia,0.98,4,33,1,0.3,False,False,,1.0,High,1.0,High-Risk Acute Myeloid Leukaemia
279728,Deciphering the role of the bone marrow microenvironment in hematological malignancies using 3D Human Organotypic Marrow Environment (3D-HOMEs),YoungEHA Research Meeting - Session 5: Microenvironment in benign and malignant hematology & Closing,Hematological Malignancy ,True,Hematologic Malignancy,0.98,2,22,0,0.1,False,False,,0.875,High,0.875,Hematologic Malignancy
296175,Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST),Colorectal cancer,First-Line Metastatic Colorectal Cancer,True,First-Line Metastatic Colorectal Cancer,0.98,4,39,1,0.3,False,False,,1.0,High,1.0,First-Line Metastatic Colorectal Cancer
296166,Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group,"Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,1.0,4,25,3,0.5,False,False,,0.684210526,Moderate,0.684210526,Early Stage Breast Cancer
165128,Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States,Adult Vaccines,Herpes Zoster Infection,True,Adult Herpes Zoster,0.98,3,19,0,0.15,False,False,,1.0,High,1.0,Adult Herpes Zoster
197882,Altered Adult Neurogenesis and Cognition in Mesial Temporal Lobe Epilepsy Patients,Evidence of adult neurogenesis in human brain and its changes with aging and disease,Mesial Temporal Lobe Epilepsy,True,Adult Mesial Temporal Lobe Epilepsy,0.98,5,35,0,0.25,False,False,,1.0,High,1.0,Adult Mesial Temporal Lobe Epilepsy
148704,Subcutaneous Immunoglobulins Use In Immunodeficiency Secondary To Chronic Lymphocytic Leukaemia: Monocentric Experience In Covid-19 Era,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Chronic Lymphocytic Leukaemia,True,Immunodeficiency Secondary to Chronic Lymphocytic Leukaemia,1.0,6,59,1,0.4,False,False,,1.0,High,1.0,Immunodeficiency Secondary to Chronic Lymphocytic Leukaemia
181510,ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Childhood Acute Myeloid Leukemia,True,Childhood Acute Myeloid Leukemia with ETS Family Transcription Factor Fusions,0.98,10,77,2,0.7,True,False,,0.587155963,Moderate,0.587155963,Childhood Acute Myeloid Leukemia with ETS Family Transcription Factor Fusions
394495,Novel Nomogram Based On The Expression Of Dll3 And Pd-L1 For Predicting The Prognosis Of Small Cell Lung Cancer Patients,Sclc,Small Cell Lung Cancer,True,DLL3 and PD-L1-Expressing Small Cell Lung Cancer,0.98,7,48,1,0.45,True,False,,1.0,High,1.0,DLL3 and PD-L1-Expressing Small Cell Lung Cancer
197863,Differential Effects of Adolescent versus Early Adult Cannabis Initiation on Longitudinal Brain Development: Evidence for Adolescence as a Period of Vulnerability,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
148732,Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology,"Enzymopathies, Membranopathies And Other Anemias",Childhood Anemia,True,Childhood Anemia,0.98,2,16,0,0.1,False,False,,0.615384615,Moderate,0.615384615,Childhood Anemia
148706,Pattern Of Minimal Residual Disease In Tunisian Chronic Myeloid Leukemia Patients,Chronic Myeloid Leukemia - Biology & Translational Research,Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,0.98,3,24,2,0.35,False,False,,1.0,High,1.0,Chronic Myeloid Leukemia
181511,Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Acute Myeloid Leukemia,True,ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia,0.98,7,53,3,0.65,True,False,,0.907216495,High,0.907216495,ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia
296164,Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial,Colorectal cancer,Microsatellite Stable pMMR Colorectal cancer,True,Class II Expressing Microsatellite Stable Colorectal Cancer,0.98,7,59,1,0.45,True,False,,1.0,High,1.0,Class II Expressing Microsatellite Stable Colorectal Cancer
197874,Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence,Cell-Type Specific Molecular Biology of Addiction,,True,Fentanyl Abstinence,0.9,2,19,0,0.1,False,False,,0.745098039,High,0.745098039,Fentanyl Abstinence
197861,Prenatal Cannabis Exposure and Outcomes during Middle Childhood,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Prenatal Cannabis Exposure,True,,0.3,0,0,0,0.0,False,False,,0.0,Low,0.0,
328968,"Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study",Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma with 1-3 Prior Therapies,0.98,7,61,3,0.65,False,False,,0.641791045,Moderate,0.641791045,Relapsed/Refractory Multiple Myeloma with 1-3 Prior Therapies
378147,AI approach for advanced analysis of flow-cytometryc data,Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence,,True,Hematological Disease,0.75,2,21,1,0.2,False,False,,0.95,High,0.95,Hematological Disease
296214,Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma,Melanoma and other skin tumours,Metastatic Uveal Melanoma,True,Metastatic Uveal Melanoma,0.99,3,25,0,0.15,False,False,,1.0,High,1.0,Metastatic Uveal Melanoma
378137,Regulation of GvHD in the hematopoietic niche,Mesenchymal stromal cells: Progress in biology and engineering of mesenchymal stromal cells,Graft-Versus-Host Disease,True,Graft-versus-Host Disease,0.98,2,25,1,0.2,False,False,,1.0,High,1.0,Graft-versus-Host Disease
312590,Orphan Non-Coding Rnas For Early Detection Of Breast Cancer With Liquid Biopsy,Detection/Diagnosis: Detection/Diagnosis - Other,Breast Cancer,True,Breast Cancer,0.98,2,13,1,0.2,False,False,,1.0,High,1.0,Breast Cancer
296202,Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA),Basic Science,Extensive Stage Small-Cell Lung Cancer,True,First-Line Extensive Stage Small Cell Lung Cancer,0.98,7,49,2,0.55,False,False,,1.0,High,1.0,First-Line Extensive Stage Small Cell Lung Cancer
148747,Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study,Hodgkin Lymphoma - Clinical,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma,True,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma,0.98,5,47,4,0.65,False,False,,1.0,High,1.0,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma
230700,Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1b and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Metastatic Pancreatic Cancer,True,Metastatic Pancreatic Cancer,0.98,3,28,1,0.25,False,False,,1.0,High,1.0,Metastatic Pancreatic Cancer
263441,Variant Haemoglobin Assessment And Correlation With Phenotypic Presentation At Diagnosis In Sickle Cell Disease : A Single Centre Retrospective Analysis Of Central Gujarat Cohort,Sickle cell disease,Sickle Cell Disease,True,Newly Diagnosed Sickle Cell Disease,0.95,5,35,2,0.45,False,False,,1.0,High,1.0,Newly Diagnosed Sickle Cell Disease
312583,Improving The Performance Of Early Breast Cancer Diagnosis By A Model Combining Breast Ultrasound With Methylation Markers In Non-Invasive Circulating Tumor Dna,Detection/Diagnosis: Detection/Diagnosis - Other,Early Breast Cancer,True,Breast Cancer,0.9,2,13,1,0.2,False,False,,1.0,High,1.0,Breast Cancer
279835,RWD of CAR T-cell therapy in older adults: The UK experience,Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe,,True,Older Adult Hematologic Malignancies,0.85,4,36,0,0.2,False,False,,0.0,Low,0.0,Older Adult Hematologic Malignancies
165143,Immunologic Hyporesponsiveness with Subsequent Dosing of Meningococcal Vaccines: Re-Evaluating the Current Paradigm,Adult Vaccines,,True,Adult Meningococcal Disease,0.95,3,27,1,0.25,False,False,,1.0,High,1.0,Adult Meningococcal Disease
296217,Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial,Melanoma and other skin tumours,High-Risk Stage III Melanoma,True,Resected High-Risk Stage III Melanoma,0.98,5,37,1,0.35,True,False,,0.72972973,High,0.72972973,Resected High-Risk Stage III Melanoma
378125,The US experience in ALL,Adult acute lymphoblastic leukemia (EWALL),Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,0.98,4,34,2,0.4,False,False,,1.0,High,1.0,Adult Acute Lymphoblastic Leukemia
410917,Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients,"AI, Digital Health, Data Science - I",Acute Kidney Injury,True,Non-Critically Ill Hospital-Acquired Acute Kidney Injury,0.98,6,56,1,0.4,False,False,,0.528301887,Moderate,0.528301887,Non-Critically Ill Hospital-Acquired Acute Kidney Injury
197935,No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,Poster Session I (In-Person),,True,Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,0.95,9,73,0,0.45,False,False,,0.615384615,Moderate,0.615384615,Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers
263509,Genetic And Epigenetic Factors Driving Primary Mediastinal B-Cell Lymphoma Pathogenesis And Outcome,Presidential Symposium,Primary Mediastinal B-Cell Lymphoma,True,Primary Mediastinal B-Cell Lymphoma,1.0,4,35,1,0.3,False,False,,1.0,High,1.0,Primary Mediastinal B-Cell Lymphoma
197955,Mutations in Kalrn Disrupt Gamma-Band Oscillations in the Auditory Cortex of Adult Mice,Poster Session I (In-Person),,True,,0.98,0,0,0,0.0,False,False,,0.0,Low,0.0,
181569,Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma,Lymphomas: Translational-Non-Genetic: Poster II,Diffuse Large B Cell Lymphoma,True,Diffuse Large B Cell Lymphoma,0.98,5,29,1,0.35,False,False,,1.0,High,1.0,Diffuse Large B Cell Lymphoma
214324,Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients with Intermediate-Risk Prostate Cancer,MP55: Prostate Cancer: Localized: Ablative Therapy,Intermediate-Risk Prostate Cancer,True,Intermediate-Risk Localized Prostate Cancer,0.98,4,43,1,0.3,False,False,,0.868421053,High,0.868421053,Intermediate-Risk Localized Prostate Cancer
148807,"Polymorphism Of Gstm1, Gstt1 And Cytokine Genes In Patients With Myelodysplastic Syndrome",Myelodysplastic Syndromes - Biology & Translational Research,Myelodysplastic Syndrome,True,"Myelodysplastic Syndrome with Gstm1, Gstt1, and Cytokine Gene Polymorphism",0.95,9,74,1,0.55,False,False,,0.5,Moderate,0.5,"Myelodysplastic Syndrome with Gstm1, Gstt1, and Cytokine Gene Polymorphism"
148806,Suppression Of Akr1B1 Reduces Cell Proliferation And Enhances Sensitivity To Hypomethylating Agents By Inhibiting Mtorc1 Signaling Pathway In High-Risk Myelodysplastic Syndrome,Myelodysplastic Syndromes - Biology & Translational Research,High-Risk Myelodysplastic Syndrome,True,High-Risk Myelodysplastic Syndrome,1.0,3,34,1,0.25,False,False,,1.0,High,1.0,High-Risk Myelodysplastic Syndrome
329014,Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Monoclonal Gammopathy,True,Monoclonal Gammopathy of Undetermined Significance with Hypercalcemia,0.98,7,69,0,0.35,False,False,,0.735294118,High,0.735294118,Monoclonal Gammopathy of Undetermined Significance with Hypercalcemia
394576,Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy By Application Of Extremity Cooling: A Prospective Single Center Study With Intrapatient Comparison,Supportive Care,Peripheral Neuropathy,True,Nail Changes;;Peripheral Neuropathy,0.98,3,35,0,0.15,False,False,,0.617647059,Moderate,0.617647059,Nail Changes;;Peripheral Neuropathy
214345,The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy,MP56: Bladder Cancer: Invasive V,Bladder Cancer,True,Invasive Bladder Cancer,0.95,3,23,1,0.25,False,False,,0.756756757,High,0.756756757,Invasive Bladder Cancer
312650,Role Of Postmastectomy Radiation Therapy In Breast Cancer Patients According To Pathologic Nodal Status After Neoadjuvant Chemotherapy,Treatment - Surgery And Radiotherapy: Radiotherapy,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,0.634146341,Moderate,0.634146341,Breast Cancer
181581,"Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma","Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II",High-Risk Elderly Mantle Cell Lymphoma,True,Elderly High-Risk Mantle Cell Lymphoma,0.98,5,38,1,0.35,False,False,,1.0,High,1.0,Elderly High-Risk Mantle Cell Lymphoma
394584,Initial Geriatric Assessment And Chemotherapy Tolerability Treatment In Brazilian Patients With Malignant Neoplasm Of The Digestive System.,Supportive Care,Malignant Neoplasm,True,Geriatric Malignant Neoplasm Of The Digestive System,0.98,7,52,0,0.35,False,False,,1.0,High,1.0,Geriatric Malignant Neoplasm Of The Digestive System
230706,"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).","Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Second-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma,True,Second-Line Locally Advanced Metastatic Esophageal Squamous Cell Carcinoma,0.98,8,74,2,0.6,False,False,,1.0,High,1.0,Second-Line Locally Advanced Metastatic Esophageal Squamous Cell Carcinoma
148814,A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),Myelodysplastic Syndromes - Clinical,Low-Risk Myelodysplastic Syndrome,True,ESA-Naive Transfusion-Dependent Low-Risk Myelodysplastic Syndromes,0.98,5,66,1,0.35,True,False,,0.594594595,Moderate,0.594594595,ESA-Naive Transfusion-Dependent Low-Risk Myelodysplastic Syndromes
263513,Ubtf-Atxn7L3 Gene Fusion Due To 17Q21.31 Deletion Defines Novel High-Risk All Subtype Amenable To Mrd-Based Treatment Intensification,From biology to preclinical models in ALL,High-Risk Acute Lymphoblastic Leukemia,True,High-Risk Acute Lymphoblastic Leukemia with Ubtf-Atxn7L3 Gene Fusion and 17q21.31 Deletion,0.98,11,90,2,0.75,False,False,,0.513513514,Moderate,0.513513514,High-Risk Acute Lymphoblastic Leukemia with Ubtf-Atxn7L3 Gene Fusion and 17q21.31 Deletion
296292,Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma,Hepatocellular carcinoma (HCC),hepatocellular carcinoma,True,Hepatocellular Carcinoma,1.0,2,24,1,0.2,False,False,,1.0,High,1.0,Hepatocellular Carcinoma
345465,A non-surgical approach to develop an orthotopic colorectal cancer mouse model,Mouse Models of Human Cancer,Colorectal Cancer,True,Colorectal Cancer,0.98,2,17,1,0.2,False,False,,1.0,High,1.0,Colorectal Cancer
148829,A Clinical-Decision Tool To Improve The Strategy Of Multiple Myeloma Treatment,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
394614,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",Supportive Care,,True,Cancer,0.9,1,6,1,0.15,False,False,,1.0,High,1.0,Cancer
345435,Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology,Tumor Organoids for Therapeutic Testing,,True,Cancer,0.9,1,6,1,0.15,False,False,,1.0,High,1.0,Cancer
148828,Validation Of Algorithms To Identify First-Line Therapy (Induction And Maintenance) For Multiple Myeloma For Use In Electronic Healthcare Databases,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,First-Line Multiple Myeloma,True,First-Line Multiple Myeloma,0.98,3,27,1,0.25,False,False,,1.0,High,1.0,First-Line Multiple Myeloma
148861,Lenalidomide Versus Thalidomide Or Bortezomib As Maintenance Regimen For Non-Transplant Patients With Multiple Myeloma: Multi-Center Real World Experiences In China,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.98,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
197976,Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma,Poster Session I (In-Person),Trauma,True,Early-Life Trauma,0.95,2,17,1,0.2,False,False,,0.790697674,High,0.790697674,Early-Life Trauma
230749,Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Hepatocellular Carcinoma,True,Hyperprogressive Hepatocellular Carcinoma,0.98,3,41,1,0.25,False,False,,1.0,High,1.0,Hyperprogressive Hepatocellular Carcinoma
230744,Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Cancer-Associated Thrombosis;;Biliary Tract Cancer,True,Biliary Tract Cancer,0.95,3,20,1,0.25,False,False,,0.555555556,Moderate,0.555555556,Biliary Tract Cancer
394619,Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors,Supportive Care,Advanced High Grade Ovarian Carcinoma,True,Advanced High Grade Ovarian Carcinoma,0.98,5,37,3,0.55,False,False,,1.0,High,1.0,Advanced High Grade Ovarian Carcinoma
296288,Real World Evidence of First-line Cetuximab (CX) plus Paclitaxel (PX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),"Head and neck cancer, excluding thyroid",Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,True,First-Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,0.98,10,76,1,0.6,False,False,,1.0,High,1.0,First-Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
279909,Classification of immunodeficiency-related lymphoproliferative disorders,Pediatric hematology: Immunodeficiency-related lymphoproliferative disorders,Immunodeficiency-Related Lymphoproliferative Disorder,True,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder,0.98,4,63,1,0.3,False,False,,1.0,High,1.0,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder
378207,Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL,Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.98,3,28,2,0.35,False,False,,0.777777778,High,0.777777778,Chronic Lymphocytic Leukemia
214394,ATM mutations are associated with high-risk architectural features in men with familial prostate cancer,MP58: Prostate Cancer: Detection & Screening VII,Familial Prostate Cancer ,True,ATM-Mutated Familial High-Risk Prostate Cancer,0.98,5,46,1,0.35,True,False,,0.804347826,High,0.804347826,ATM-Mutated Familial High-Risk Prostate Cancer
148877,Analysis Of Delay In The Diagnosis Of Multiple Myeloma In A Sanitary Region Of Southern Spain.,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,1.0,2,16,1,0.2,False,False,,1.0,High,1.0,Multiple Myeloma
279967,How will we treat high-risk multiple myeloma in the future?,Janssen: Immunotherapy: evolution or revolution in the cure of multiple myeloma,High-Risk Multiple Myeloma,True,High-Risk Multiple Myeloma,0.98,3,26,1,0.25,False,False,,1.0,High,1.0,High-Risk Multiple Myeloma
198028,Exposure to Prenatal Stress Induces Sex-Specific Vulnerability to Psychopathologic Domains in Adolescent Rats,Poster Session I (In-Person),,True,Adolescent Psychopathologic Domains,0.9,3,35,0,0.15,False,False,,1.0,High,1.0,Adolescent Psychopathologic Domains
312718,Efficacy And Safety Of Pyrotinib-Based Therapy In The Treatment Of Her2-Positive Breast Cancer Patients With Brain Metastases:A Multi-Center Real-World Study,Treatment - Types And Sites Of Breast Cancer: Brain Metastases,Brain Metastasis;;Her2-Positive Breast Cancer,True,HER2-Positive Breast Cancer with Brain Metastases,0.98,6,49,2,0.5,False,False,,1.0,High,1.0,HER2-Positive Breast Cancer with Brain Metastases
329101,Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,Multiple Myeloma,True,MRD-Negative Multiple Myeloma,0.85,3,29,2,0.35,True,False,,0.711111111,High,0.711111111,MRD-Negative Multiple Myeloma
